Purdue University

Purdue e-Pubs
Open Access Dissertations

Theses and Dissertations

5-2018

The Impact of Host Variables and Tumor Necrosis Factor on the
Gut Microbiome in a Mouse Model of Crohn's Disease
Ariangela J. Kozik
Purdue University

Follow this and additional works at: https://docs.lib.purdue.edu/open_access_dissertations

Recommended Citation
Kozik, Ariangela J., "The Impact of Host Variables and Tumor Necrosis Factor on the Gut Microbiome in a
Mouse Model of Crohn's Disease" (2018). Open Access Dissertations. 1750.
https://docs.lib.purdue.edu/open_access_dissertations/1750

This document has been made available through Purdue e-Pubs, a service of the Purdue University Libraries.
Please contact epubs@purdue.edu for additional information.

THE IMPACT OF HOST VARIABLES AND TUMOR NECROSIS
FACTOR ON THE GUT MICROBIOME IN A MOUSE MODEL OF
CROHN’S DISEASE
by
Ariangela J. Kozik

A Dissertation
Submitted to the Faculty of Purdue University
In Partial Fulfillment of the Requirements for the degree of

Doctor of Philosophy

Department of Comparative Pathobiology
West Lafayette, Indiana
May 2018

ii

THE PURDUE UNIVERSITY GRADUATE SCHOOL
STATEMENT OF COMMITTEE APPROVAL

Dr. Yava L. Jones-Hall, Co-Chair
Department of Comparative Pathobiology
Dr. Cindy H. Nakatsu, Co-Chair
Department of Agronomy
Dr. Harm HogenEsch
Department of Comparative Pathobiology
Dr. Hyonho Chun
Department of Statistics

Approved by:
Dr. Sanjeev Narayanan
Head of the Graduate Program

iii

To God, who gives the mind and the opportunities to understand life’s mysteries.
To my husband Allen, whose constant love and support carried me through this journey.
To Gabriel, who reminds me to laugh.
To my parents, who planted and watered the seeds of curiosity from day one.
To my in-laws, family, and friends who provided support, meals, and free babysitting.
To Mrs. Marvin and Ms. Bell, whose passion for education continues to inspire me.
Thank you

iv

ACKNOWLEDGMENTS

Thank you to Jayda, Tamanna, Tierra, and Taylor for helping with animal experiments and data
collection.

Thank you to my lab mates Clayton, Kilia, and YooJung for your help with sample prep and for
the many paper and data discussions.

Thank you to Dr. Colleen Gabauer, Dr. Kauline Cipriani, and Dr. Linda Mason for personal and
professional mentoring and support.

Thank you to Dr. Yava L. Jones-Hall and Dr. Cindy H. Nakatsu for encouraging my academic
growth, and always pushing me to do better.

Thank you to Arthur P. Armstrong for processing and preparing samples.

Thank you to the Purdue Histology Research Laboratory for histology services.

Thank you to the Purdue University Laboratory Animal Facility for animal housing and
husbandry services.

Thank you to the Purdue Genomics Facility for sequencing services and the Purdue
Bioinformatics Core for access to computational resources.

v

TABLE OF CONTENTS

LIST OF FIGURES ..................................................................................................................... viii
ABSTRACT................................................................................................................................. xiii
CHAPTER 1. INTRODUCTION ................................................................................................ 1

1.1

Inflammatory Bowel Disease.............................................................................................. 1

1.1.1

Symptoms, Prevalence, and Risk factors..................................................................... 1

1.1.2

Distinct features of Crohn’s Disease and Ulcerative Colitis ....................................... 2

1.1.3

Current Treatments ...................................................................................................... 3

1.2

Tumor Necrosis Factor ....................................................................................................... 5

1.3

The human gut microbiome ................................................................................................ 7

1.3.1

The gut microbiome is closely connected to the immune system ............................... 8

1.3.2

Gut microbes as regulators of homeostasis ................................................................. 8

1.3.3

The human gut microbiome in IBD............................................................................. 9

1.4

Mouse models in IBD research......................................................................................... 10

1.4.1

Mouse models of colitis............................................................................................. 11

1.4.2

Chemically-induced models of colitis ....................................................................... 11

1.4.2.1 TNBS Colitis ........................................................................................................ 12
1.4.3

The relevance of the mouse gut microbiome to the human gut microbiome ............ 13

1.4.4

The interface of TNF, the gut microbiome, and IBD ................................................ 14

1.4.5

Factors affecting the gut microbiome in animal studies............................................ 15

1.5

Summary ........................................................................................................................... 16

CHAPTER 2.

THE IMPACT OF AGE, SEX, AND TNF ON THE GUT MICROBIOTA IN A

MOUSE MODEL OF COLITIS................................................................................................... 19
2.1

Introduction....................................................................................................................... 19

2.2

Methods............................................................................................................................. 21

2.2.1

Mice ........................................................................................................................... 21

2.2.2

Acute Colitis .............................................................................................................. 21

2.2.3

Histological Assessment of Colitis............................................................................ 22

2.2.4

DNA Extraction and Sequencing............................................................................... 22

2.2.5

Sequence Analysis ..................................................................................................... 23

vi
2.2.6
2.3

Statistics..................................................................................................................... 23

Results............................................................................................................................... 24

2.3.1

Significant variation in the microbiome by experiment ............................................ 24

2.3.2

Female WT mice and Tnf-/- mice of both sexes have less colitis than male WT mice
................................................................................................................................... 24

2.3.3

Sex contributes to differences in the fecal microbiome pre-colitis ........................... 25

2.3.4

Alterations in the fecal microbial composition of Male and Female Mice after TNBS

colitis ................................................................................................................................... 26
2.3.5

Age contributes to differences in colitis severity and the gut microbiome composition

of WT and Tnf-/- mice ............................................................................................................ 26
2.3.6

Canonical Correspondence Analysis confirms TNF, Sex, and Age as significant

factors contributing to differences in the fecal microbiome. ................................................. 27
2.4

Discussion ......................................................................................................................... 27

CHAPTER 3. SPATIAL COMPOSITION OF THE GUT MICROBIOME ASSOCIATED

WITH SEX, TNF, AND CHRONIC TNBS COLITIS................................................................. 40
3.1

Introduction....................................................................................................................... 40

3.2

Methods............................................................................................................................. 41

3.2.1

Mice ........................................................................................................................... 41

3.2.2

Chronic TNBS Colitis................................................................................................ 41

3.2.3

Histological Assessment of Colitis............................................................................ 42

3.2.4

DNA Extraction and Sequencing............................................................................... 42

3.2.5

Sequence Processing.................................................................................................. 42

3.2.6

Statistical Analysis..................................................................................................... 43

3.3

Results – Chronic TNBS colitis in WT mice.................................................................... 45

3.3.1

Sex impacts chronic TNBS colitis in WT mice......................................................... 45

3.3.2

TNBS treatment results in significant alterations in the microbiomes the feces,

cecum, and the mucus of WT mice ....................................................................................... 45
3.3.2.1 TNBS associated differences in microbial diversity. ........................................... 45
3.3.2.2 TNBS associated differences in community composition.................................... 46
3.3.3

The mucus microbiome is more closely associated with colitis than is that of the

feces or cecum ....................................................................................................................... 46

vii
3.4

Results- Chronic TNBS colitis in Tnf -/- mice compared to WT mice.............................. 47

3.4.1

The fecal microbiomes of WT and Tnf -/- mice pre and post colitis are distinct........ 47

3.4.1.1 Significant differences in microbial diversity ...................................................... 47
3.4.1.2 Significant differences in community composition.............................................. 47
3.4.2

Tnf -/- mice tend to have less severe chronic TNBS colitis than WT mice ................ 48

3.4.3

The cecal microbiomes of WT and Tnf -/- mice with colitis are distinct.................... 48

3.4.3.1 Significant differences in microbial diversity ...................................................... 48
3.4.3.2 Significant differences in community composition.............................................. 48
3.4.4
3.5

Sex impacts the cecal microbiome of Tnf -/- mice with colitis ................................... 48

Discussion ......................................................................................................................... 49

CHAPTER 4.

THE GUT MICROBIOME ACROSS three commonly used STRAINS OF

LABORATORY MICE ................................................................................................................ 68
4.1

Introduction....................................................................................................................... 68

4.2

Methods............................................................................................................................. 69

4.2.1

Mice ........................................................................................................................... 69

1.2.2 DNA Extraction and Sequencing.................................................................................. 69
4.2.2

Data Analysis............................................................................................................. 69

4.2.3

Statistics..................................................................................................................... 69

4.3

Results............................................................................................................................... 70

4.3.1

Mouse strain is associated with significant differences in fecal microbiome diversity
................................................................................................................................... 70

4.3.2

BALB/c, B6.129S, and C57BL/6J mice have different taxonomic profiles ............. 70

4.3.3

Vendor and Sex associated effects in the fecal microbiome ..................................... 71

4.4

Discussion ......................................................................................................................... 72

CHAPTER 5. SUMMARY ........................................................................................................ 83

APPENDIX A. NO SEX ASSOCIATED DIFFERENCES IN COLITIS IN MICE LACKING
TNF ......................................................................................................................................... 89
APPENDIX B. NO SIGNFICANT SEX ASSOCIATED DIFFERENCES IN THE
FECALMICROBIOMES OF WT MICE PRE-COLITIS ...................................................... 91
REFERENCES ............................................................................................................................. 92
VITA ........................................................................................................................................... 109

viii

LIST OF FIGURES

Figure 2.1 Significant differences in beta-diversity associated with experiment. Principal
Coordinate Analysis (PCoA) of the Bray Curtis metric shows significant separation on PC1
associated with experiment. PERMANOVA p<0.01. PC1 explains 23.17% of the total variation.
....................................................................................................................................................... 32
Figure 2.2 Female WT mice and Tnf-/- mice of both sexes have less colitis than male WT mice.
H&E of representative photomicrographs of the colons of A. male TNBS treated WT (n=4) and
B. female TNBS treated WT (n=10); C. male TNBS treated Tnf-/- (n=3) and D. female TNBS
treated Tnf-/- mice (n=10). E. Histopathological semi-quantitative scores are presented as the
mean score ± SEM. Scale bar is 100µm. Significant differences found using Kruskal-Wallis for
overall significance, followed by pairwise Mann-Whitney tests. Asterisks indicate significance.
p<0.05. Mice shown are mixed ages (4-8 weeks)......................................................................... 33
Figure 2.3 Sex contributes to differences in the fecal microbiome pre-colitis. ............................ 34
Figure 2.4 Taxa that contribute significantly to the differences between male and female mice of
both genotypes. A. LEfSe histogram of taxa that are significantly more abundant in male and
female Tnf--/- mice, post-colitis (female n=19 male n=4) p-value <0.05 considered significant B.
LEfSe histogram of identified significantly more abundant taxa in male and female WT mice
post-colitis (female n=20 male n=6) and their effect sizes; p -values <0.05 considered significant.
....................................................................................................................................................... 35
Figure 2.5 Age contributes to differences in colitis severity and the gut microbiome composition
of WT and Tnf-/- mice A. Representative H&E stained photomicrographs of the colons of WT
TNBS and Tnf--/- TNBS treated mice (WT 4-5-week-old mice, n=5; WT 6-7-week-old mice, n=5,
Tnf--/- 4-5-week-old mice, n= 5; Tnf--/- 6-7-week-old mice, n=8). Scale bar is 100µm. B.
Histopathological semi-quantitative WT and Tnf--/- colitis scores of both age groups are presented
as mean ± SEM. Significant differences found using overall ANOVA followed by pairwise
Mann-Whitney test. * indicates significance p<0.05, ** indicate significance p< 0.01. ............. 36
Figure 2.6 Taxa that contribute significantly to differences in the fecal microbiome of WT mice
associated with age. A. Histogram of the results of LEfSe associated with age in WT mice precolitis (4-week-old mice, n=12; 6-7-week-old mice, n=10); all taxa shown are significant at
p<0.05. B. Cladogram representing the identified pre-colitis WT age-related differentiating taxa
in a taxonomic tree that emphasizes their phylogenetic relationship. Shaded areas distinguish
branches on the tree that correspond to experimental groups. C. Histogram of the results of
LEfSe of associated with age in WT TNBS treated mice post-colitis and their respective effect
sizes; p-values < 0.05 considered significant. D. Cladogram representing the identified postcolitis WT TNBS treated -age related differentiating taxa in a taxonomic tree. .......................... 37

ix
Figure 2.7 Taxa that contribute significantly to differences in the fecal microbiome of Tnf--/-mice
associated with age. A. Histogram of the results of LEfSe of associated with age in Tnf--/- TNBS
mice pre-colitis and their respective effect sizes (4-5-week-old mice, n=10; 6-7-week-old mice,
n= 13); p values < 0.05 considered significant. B. Cladogram representing pre-colitis Tnf--/TNBS age related differentiating taxa in a taxonomic tree. C. Histogram of differentiating taxa
associated with age in Tnf--/- TNBS mice post-colitis and their respective effect sizes; p-values <
0.05 considered significant. .......................................................................................................... 38
Figure 2.8 Age, sex, and TNF status are significant factors influencing the fecal microbiome and
colitis severity. CCA model was performed with day 10 fecal microbiome relative abundances as
the species matrix and the environmental variables of Age, Sex, colitis (score), and Genotype
included in the environmental matrix. Variable biplot arrows indicates direction of
environmental gradient. Relative length of arrows corresponds to the importance of the
respective variables in our model. Angle between arrows corresponds to the relationship of the
environmental variables to one another. Age and Colitis score are closely associated with each
other. Overall p=0.003. Axes 1, 2, and 3 explain 51.0%, 23.5%, and 19.6% of the total
constrained variation..................................................................................................................... 39
Figure 3.1 A. Bar Graph colitis scores in WT TNBS and WT SHAM treated mice. ****T-test
p<0.0001. Values plotted as Mean ± SEM B. Bar graph of differences in colitis score by sex in
WT TNBS and WT SHAM treated mice. T-test *p<0.05 ,**p<0.01. Values plotted as Mean ±
SEM. C. Survival curve of WT male and female mice with chronic TNBS colitis compared to
SHAM treated mice. Significant differences found using Mantel-Cox test. *p<0.05 D.
Representative photomicrographs of hematoxylin and eosin stained colon tissues. Pictures taken
at 20X magnification. Scale bar is 100um. ................................................................................... 54
Figure 3.2 A. Pairwise Shannon diversity comparisons across body sites of TNBS and SHAM
treated mice post-colitis. Significance found with non-parametric T-test p<0.05 B. Significant
differences in beta diversity in the feces of TNBS and SHAM treated mice post-colitis calculated
using the Bray Curtis metric. Treatment separates along PC1, which explains approximately 30%
of the total variation in the data. Significance found with PERMANOVA p<0.05. PERMDISP
indicates dispersion does not contribute to significance. C. Significant differences in beta
diversity in the colon mucus of TNBS and SHAM treated mice post-colitis calculated using
Weighted UniFrac. Treatment separates along PC1, which explains approximately 76% of the
total variation in the data. Significance found with PERMANOVA p<0.05. PERMDISP indicates
dispersion does not contribute to significance. ............................................................................. 55
Figure 3.3 PCoA of the Unweighted UniFrac metric reveals significant differences in beta
diversity by spatial distribution, regardless of treatment. Site separates along PC1 and PC2,
explaining 20% and 12.6% of the total variation, respectively. Significance found with
PERMANOVA p<0.05. PERMDISP indicates that dispersions does not contribute to
significance. .................................................................................................................................. 56
Figure 3.4 A.Taxonomic profile comparisons of major phyla in TNBS and SHAM treated
samples in each site. Significance indicated by asterisk. Significance found using ANOVA with
pairwise follow-up tests. P values corrected for multiple comparisons. B. Taxonomic profile
comparisons of minor phyla in TNBS and SHAM treated samples in each site. Significance

x
(p<0.05) indicated by asterisk. Significance found using Kruskal-Wallis with pairwise follow-up
tests. P values corrected for multiple comparisons with Dunn’s test. .......................................... 57
Figure 3.5 Plots of significantly different taxa across body sites and treatment groups. Overall
significance found using ANCOM. Follow-up pairwise tests were performed, and p values were
corrected for multiple comparisons using False Discovery Rate. *p<0.05, **p<.01, ***p<0.001,
****p<0.0001 ............................................................................................................................... 58
Figure 3.6 Co-occurrence modeling of the interaction network of WT mucus shows within and
between phylum interactions. Circles (nodes) represent taxa, and lines connecting nodes
represent an interaction between two taxa. Circle size indicates with how many nodes with
significant interactions were identified. Node color indicates the phylum that a particular taxon
belongs to. ..................................................................................................................................... 59
Figure 3.7 Canonical Correspondence Analysis on the relative taxon abundances reveals that
colitis score is more closely associated with the mucus microbiome than the fecal microbiome.
Feces is closely associated with CCA1, which explains 52.6% of the constrained variation.
TNBS treatment and colitis score was associated with CCA2 and CCA3, which explains 23.8%
and 15.2%of the constrained variation, respectively. Significance found using ANOVA p=0.001
....................................................................................................................................................... 60
Figure 3.8 A. Comparison of the Shannon diversity metric pre-colitis shows that WT mice have
significantly lower alpha diversity than Tnf-/- mice. Monte Carlo test p<0.05 B. Analysis of the
Bray Curtis metric pre-colitis shows that there are significant genotype-associated differences in
beta-diversity of the fecal microbiomes. Genotype separates on PC1, which explains 62% of the
total variation in the data. Significance considered p<0.05 using PERMANOVA. PERMDISP
indicates that dispersion does not contribute to significance. C. Comparison of the Shannon
diversity metric post-colitis shows that WT mice have significantly lower alpha diversity than
Tnf-/- mice. Monte Carlo test p<0.05 D. Analysis of the Bray Curtis metric post-colitis shows that
there are significant genotype-associated differences in beta-diversity of the fecal microbiomes
of WT and Tnf-/- mice. Genotype separates on PC1, which explains approximately 35.48% of the
total variation in the dataset. PERMANOVA p=0.001, PERMDISP p=0.001............................. 61
Figure 3.9 Histogram of the effect sizes of LEfSe identified taxa that contribute to the differences
between WT and Tnf-/- mice pre-colitis. ....................................................................................... 62
Figure 3.10 Graph of colitis scores in WT and Tnf-/- mice TNBS treated mice. Data shown as
mean + S.E.M. Significance tested using Mann-Whitney test. .................................................... 63
Figure 3.11 A. Comparison of the observed species metric post-colitis shows that WT mice have
significantly lower alpha diversity than Tnf-/- mice. Monte Carlo test p<0.05 B. Analysis of the
Weighted UniFrac metric post-colitis shows that there are significant genotype-associated
differences in beta-diversity of the cecal microbiomes of WT and Tnf-/- mice. Genotype separates
on PC1, which explains approximately 64.48% of the total variation in the dataset.
PERMANOVA p=0.001, PERMDISP n.s. C. Comparison of the Shannon diversity metric postcolitis shows that WT mice have significantly lower alpha diversity than Tnf-/- mice. Monte Carlo
test p<0.05..................................................................................................................................... 64

xi
Figure 3.12 Histogram of the effect sizes of LEfSe identified taxa contributing to TNF associated
differences in the cecum of mice post-colitis ............................................................................... 65
Figure 3.13 Histogram of the effect sizes of LEfSe identified taxa that contribute to sex
differences in Tnf-/- mice. .............................................................................................................. 66
Figure 4.1 Quantities and sex of mice strains used for analysis, separated by vendor................. 75
Figure 4.2 Alpha diversity plots of B6.129, BALB/c, and C57BL/6J fecal microbiomes. A.
Boxplots of observed species metric reveals significant differences in species richness across
mouse strains. Significance determined using non-parametric t-test with 999 permutations.
Asterisk indicates significance at p<0.05 B. Boxplots of Shannon diversity metric reveals
significant differences in Shannon diversity across mouse strains. Significance determined using
non-parametric t-test with 999 permutations. Asterisk indicates significance at p<0.05 ............. 76
Figure 4.3 Differences in beta-diversity of the fecal microbiomes of B6.129S, BALB/c, and
C57BL/6J mice. A. Bray Curtis metric shows separation of communities based on strain
(p<0.05). Separation occurs on PC1 and PC2, which explain 31.08% and 19.23% of the total
variation, respectively. Significance was found using PERMANOVA. Significant PERMDISP
(p<0.05) indicates that dispersion may contribute to significance. B. Unweighted UniFrac metric
shows separation of communities based on strain (p<0.05). Separation occurs on PC1 and PC2,
which explain 18.75% and 14.25% of the total variation, respectively. Significance was found
using PERMANOVA. Significant PERMDISP (p<0.05) indicates that dispersion may contribute
to significance. .............................................................................................................................. 77
Figure 4.4 A. Taxonomic profiles of each mouse strain. Asterisks indicate significant difference
(adj. p<0.05) computed by ANOVA with multiple comparisons................................................. 78
Figure 4.5. Heatmap of significantly different taxa in each strain. Relative abundances of taxa
identified by ANCOM to be significantly different between mouse strains at p<0.01. Blue
represents a relative abundance of 0, and color gradient increases to yellow as relative abundance
increases. Superscript lowercase letters indicate which taxa remained significant different after
pairwise post- testing and correcting for multiple corrections. Significance is considered an
adjusted p value of less than 0.05 ................................................................................................. 79
Figure 4.6 Significant differences in beta-diversity associated with vendor, and sex within strain.
A. Bray Curtis metric shows significant differences in beta-diversity associated with vendor.
PERMANOVA p<0.001. PERMDISP p<0.05 indicates dispersion may contribute to significance.
B. Bray Curtis metric shows significant differences in beta diversity associated with sex within
mouse strains. PERMANOVA p<0.001. C. Unweighted UniFrac metric shows significant
differences in beta-diversity associated with source. PERMANOVA p<0.001 D. Unweighted
UniFrac metric shows significant differences in beta-diversity associated with sex within mouse
strains. PERMANOVA p<0.001 ................................................................................................. 80
Figure 4.7 Community profiles of male and female mice of difference strains at the genera level.
....................................................................................................................................................... 81

xii

Figure 4.8 Significantly different taxa associated with sex within strains. A. Histogram of the
effect sizes of taxa that Lefse identified as being significantly contributing to the differences
between mouse strains and sexes. B-E. Bar graphs of relative abundance of select genera in male
and female B6.129S mice and male and female C57BL6J mice. Significance found using
ANCOM followed by pairwise post-tests. P values were adjusted for multiple comparisons. **
p<0.01, ***p<0.001, ****p<0.0001. D. Bar graph of colitis scores of male and female C57BL6J
mice with chronic TNBS colitis. Asterisk indicates significance at p<0.05 using Mann-Whitney
test. ................................................................................................................................................ 82

xiii

ABSTRACT

Author: Kozik, Ariangela, J. PhD
Institution: Purdue University
Degree Received: May 2018
Title: The Impact of Host Variables and Tumor Necrosis Factor on the Gut Microbiome in a
Mouse Model of Crohn’s Disease
Committee Chair: Dr. Yava L. Jones-Hall
Crohn’s Disease (CD) and Ulcerative Colitis (UC) are chronic, inflammatory conditions of the
digestive tract that are collectively known as Inflammatory Bowel Disease (IBD). Currently, IBD
has no cure and the exact mechanisms of disease development and progression are unknown.
The gut microbiome is the collection of microbes that reside in the digestive tracts of humans
and animals, and it has been shown to be associated with a variety of diseases, including IBD.
Mouse models of colitis are often used to investigate the role of the gut microbiome in IBD. In
this work, I investigated the role of tumor necrosis factor (TNF) on the gut microbiome in a
mouse model of CD. Tumor necrosis factor is an inflammatory cytokine that plays a critical role
in the inflammatory response. A common IBD treatment strategy is the use of TNF inhibitors.
However, a subset of patients only responds to anti-TNF treatment for a limited time, while
others do not respond at all. It is not fully understood how TNF, or TNF blockade, impacts the
microbiome. Therefore, my overall objective was to determine how TNF and host variables
impact the mouse gut microbiome during colitis. My hypotheses were that 1) Age, sex, and TNF
affect

the

fecal

microbiome

of

mice,

and

impact

the

severity of

acute

2,4,6

trinitrobenzenesulfonic acid (TNBS) colitis. 2) TNF, sex and disease severity impact the
microbiome in chronic TNBS colitis and the composition of the fecal microbiome will closely
correlate with colitis severity. 3) Different mouse strains have a distinct fecal microbiome. To
test my hypotheses, I induced acute and chronic TNBS colitis in WT mice and Tnf-/- mice. 16S
rRNA gene sequencing, microbiome analysis, and multivariate analyses were used to determine
the relationship of host factors to the gut microbiome. I found that TNF, age, and sex impact the
gut microbiome in mice before and after colitis. Additionally, I identified specific microbes that
are differentially abundant depending on TNF expression, GI site, as well as the mouse age, sex,
strain, and vendor. This work highlights the importance of considering host factors in

xiv
microbiome studies and provides important data to the literature concerning the role of the gut
microbiome in IBD pathogenesis.
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CHAPTER 1.

INTRODUCTION

Microorganisms inhabit virtually every known environment. Although most are invisible to us
without technology, Bacteria, fungi, Archaea, and viruses are some of the oldest and most
abundant life forms on Earth [134]. Advances in sequencing technologies and analyses have
allowed scientists to explore the populations of microbes and their genomes (or microbiomes) of
several natural ecosystems such as: soil, the ocean, hydrothermal vents, and Artic ice [8,13,18].
Of these microorganisms, Bacteria have been the most extensively studied. Improved sequencing
technologies have also enabled the investigation of the microbiomes in several niches of humans
and animals. These technologies have also revealed that the microbiomes of humans are
connected to host physiology and are therefore integral to human health. Microbiome studies that
compare healthy individuals to diseased individuals have identified differences in their microbial
communities associated with lifestyle, genetics, and immune outcomes [217]. In this work, I
examine the impact of tumor necrosis factor (TNF), an inflammatory mediator, on the gut
microbiome in a mouse model of a subtype of Inflammatory Bowel Disease called Crohn’s
Disease.

1.1
1.1.1

Inflammatory Bowel Disease
Symptoms, Prevalence, and Risk factors

Inflammatory Bowel Disease (IBD) can refer to either of two subtypes of chronic, relapsing
inflammation in the GI tract, Crohn’s Disease (CD) and Ulcerative Colitis (UC). IBD affects
approximately 3 million Americans [44]. People who suffer from IBD endure a myriad of
distressing symptoms, such as diarrhea, abdominal pain, vomiting, bloody and watery stool, and
malnutrition. These symptoms greatly reduce quality of life, and despite advances in therapeutic
approaches, IBD remains uncured [266]. IBD can develop in children as well as adults, and has
historically been more prevalent in developed, Western countries. IBD patients often undergo
surgery to slow disease progression, which adds to the already high cost of missed work due to
episodes of severe symptom activity and that of treatments aimed at symptom relief. A 2003
study estimated the total cost of IBD in the United States to be approximately $3.6 billion USD
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per year [138]. The cause of IBD is unknown, but research has suggested that genetic and
environmental factors are at play. A family history of IBD is considered a risk factor, and we are
aware of more than 100 distinct genetic risk loci implicated in IBD [5,115]. However, data
suggests that even if an individual carries a susceptibility allele, other factors are still needed for
disease to occur [115].The contribution of environmental factors to IBD risk is complex. Studies
have revealed that environmental factors weigh differently between CD and UC. Twin studies
have reported a 20-50% concordance rate for CD, while only 10-15% concordance in UC [58].
This suggests that environmental triggers may have more influence in UC versus CD [224]. Diet,
smoking history, antibiotic use, and a history of enteric infection have all been identified as risk
factors in IBD, albeit the impact of some these factors are not consistent across IBD subtypes.
Smoking, for example, has been shown to increase the risk of CD [5,17,40,42]. Smokers are also
more likely to experience aggressive CD that leads to more surgeries and relapses than nonsmokers [40,41]. Additionally, smoking cessation has been shown to increase the risk of UC [97].

Diet has also been strongly associated with IBD risk; consumption of fiber from fruits and
vegetables has been inversely correlated with CD risk in children and adults [4,100].Additionally,
increased intake of animal protein may be associated with CD [107]. Moreover, geographic
regions like Asia that are shifting towards a more westernized (low fiber, high fat, highly
processed) diet are experiencing increases in the incidence of CD and UC [176,177]. The
continued spread of IBD worldwide with its accumulating costs and negative impact on quality
of life continue to drive research into the exact mechanisms of each subtype and the development
of curative treatments.
1.1.2

Distinct features of Crohn’s Disease and Ulcerative Colitis

As previously stated, IBD has two phenotypes- CD and UC. While these diseases are considered
sub-types of IBD and share similarities in their symptoms, it is important to consider the distinct
differences between them. Patients with CD experience inflammation that can affect any portion
of the gastrointestinal tract, from mouth to anus. CD is generally diagnosed via endoscopy,
where the presence of patchy areas of inflamed tissue, referred to as ‘cobblestoning’ and/or
thickening of the intestinal wall are considered hallmarks of the condition [65]. Due to the patchy
characteristic of CD inflammation, there are often areas of healthy tissue adjacent to the diseased
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areas. Another important characteristic of CD is that the inflammation can be transmural,
affecting all layers of the bowel wall. Conversely, UC only occurs in the colon and is
characterized by continuous areas of inflammation that is restricted to the mucosa. Rather than a
thickening of the intestinal wall as seen in CD, UC patients typically have a thin intestinal wall
[171,237]. Beyond morphological differences, CD and UC also differ in their inflammatory
processes.

In general, inflammation is driven by cytokines. Cytokines are small secreted proteins that
function as signaling molecules. They orchestrate the coordinated response of immune cells to
invading microbial threats and regulate inflammation at the local and systemic level. The
cytokines TNFα, IL-1β and IL-6 have a broad range of effects during inflammation, one of
which is guiding differentiation of T helper (Th) cells [174,228]. Differentiation occurs when
antigen presenting cells prime naïve Th cells with foreign material or microbial components
(possibly derived from the microbiota) and the cytokines present can further promote
differentiation of specific Th cell subsets. The activated Th cells coordinate the adaptive immune
response by activating B cells, macrophages, or cytotoxic T cells [3].

T helper cells are

differentiated by the distinct sets of cytokines they produce, and lead to different adaptive
immune responses [3]. T helper type 1 cells secrete tumor necrosis factor (TNF) and interferon
gamma (IFN-γ) and act mainly to activate macrophages and cytotoxic T cells to eliminate
intracellular microbial pathogens. Interleukin-12 (IL-12) is also associated with a Th1 response
and is secreted by macrophages and dendritic cells (DCs). T-helper type 2 cells secrete IL-4, IL5, and IL-13 and act mainly to activate B cells to eliminate extracellular pathogens [14]. Th17
cells secrete IL-17, IL-21, and IL-22 in addition to other functions that are thought to activate
cytotoxic T cells as well as play a role in autoimmunity [186]. Th17 cells are abundant in the
intestine and are thought to be involved in immune responses at mucosal surfaces [174]. In IBD,
UC is characterized by a Th2 response whereas CD is characterized by a mixed Th1/Th17
response [228].
1.1.3

Current Treatments

As there is currently no cure for IBD, treatment regimens focus on ameliorating symptoms.
Current treatment options include, but are not limited to, anti-inflammatory drugs,
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immunosuppressants, antibiotics, and biologics designed to inhibit various signaling pathways.
Each of these options is used alone or in combination and exhibit varying degrees of efficacy often by IBD subtype. One such option is 5-aminosalicylates which are anti-inflammatory drugs
used to induce remission in UC patients. They are thought to work by inhibiting the nuclear
factor kappa beta (NFκB) pathway in immune cells, as well as suppressing pro-inflammatory
cytokine production and prostaglandin synthesis [175].

Corticosteroids are another class of widely-used drugs. They have been shown to reduce
inflammation, partially by inactivation of the NF B pathway [258], which subsequently
decreases expression of pro-inflammatory cytokines IL-1 and IL-6. Corticosteroids are effective
for inducing remission in both UC and CD, but due to the numerous negative side effects
associated with prolonged corticosteroid use these drugs are only used temporarily. Drugs such
as methotrexate, cyclosporine A, tacrolimus and azathioprine can also induce and maintain
remission, but these powerful drugs leave the patient more susceptible to infection due to potent
suppression of the immune system. Antibiotics are also used as a treatment option for IBD. It is
thought that the reduction in overall bacterial load may ease symptoms, which essentially
provides physical space that allows for the growth of more beneficial bacteria. Additionally,
antibiotics are useful in treating the infections that often arise as complications of IBD [180].
However, antibiotics alter the microbiome in profound ways, and prolonged use carries a risk of
the development of dangerous opportunistic and drug-resistant infections.

Perhaps the most popular type of drugs used for treatment of IBD is biologics that inhibit the
function of tumor necrosis factor (TNF). Tumor necrosis factor is a cytokine that is critical to the
immune response. It has widespread pro- and anti-inflammatory actions, which will be discussed
below. Anti-TNF drugs were developed to limit the immune response in IBD patients [131].
Despite their wide-spread use, these drugs are sometimes not tolerated by IBD patients, leading
to adverse reactions and complications [136]. In other cases, the drugs only work for a short
period of time or not at all: as many as 50% of IBD patients fail to respond to anti-TNF agents
after as little as one year of use [238]. Additionally, anti-TNF therapy can have dangerous side
effects. Patients experience increased risk of opportunistic infections, lymphoma, and sometimes
develop autoimmunity as a result of their suppressed immune systems [226]. There is continuing
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research into new therapies for IBD, with targets such as other cytokines like IL-6 [46] and Tcells themselves [167].

Lastly, probiotics (live organisms that are beneficial to host health) have also been studied as
potential treatments for IBD [36]. Several studies examining probiotic therapies in UC patients
have shown promise, but there has been little to no progress in finding an effective probiotic
therapy for CD [94,149,212,240]. One probiotic mixture has shown promising results in clinical
studies in UC patients. VSL#3 is a commercially available mixture of 8 Gram-positive probiotics
that has shown some degree of effectiveness in various UC studies [10,53,240] .

Aside from antibiotics and probiotics, the effect of these drugs on the microbiome has yet to be
determined. Given that IBD is considered, in part, to be a microbe-mediated disease, it is
imperative for future studies to consider the impact of potential therapeutics on the gut
microbiome. Despite our knowledge that select bacterial strains have specific beneficial effects,
our ability to translate these benefits to therapies is limited. It is therefore critical for IBD
microbiome studies to maintain an ecological, whole-community perspective if we hope to fully
understand the relationship between the gut microbiome and the intestinal immune system in
IBD. Moreover, therapies that replace the entire fecal microbiota of a patient with that of a
healthy individual (fecal microbiome transfer, FMT) has shown higher rates of remission in CD
compared to UC [12,188]. This suggests that the dysbiosis in UC is different from the dysbiosis
seen in CD, where the replacement of the entire function of the fecal microbiome was needed (as
in FMT) for a positive response to be seen.

1.2

Tumor Necrosis Factor

Tumor necrosis factor is a cytokine that plays a critical role in the inflammatory response. It
belongs to a superfamily of 19 ligands and 29 receptors with 3 additional receptors specific to
mice. TNFα (now named TNF) and TNFβ (now named lymphotoxin) were first identified as
proteins with antitumor activity [1]. TNF is secreted by macrophages, natural killer T cells
(NKT), B cells, and T cells [1,192,234]. Often called a ‘master regulator’, TNF can both initiate
inflammation and suppress autoimmunity [121]. TNF secretion can be stimulated by trauma,
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infection, and the presence of bacteria as signaled by bacterial products like lipopolysaccharide
LPS [114,192,234]. In addition to its role in activating the immune response, TNF can also
promote programmed cell-death [192] and T cell tolerance [250]. When an immunogenic
stimulus is encountered, TNF is secreted, activating any of a number of signaling pathways, such
as NfκB, to neutralize the stimulus and repair the affected tissues in a controlled fashion [136].

TNF has soluble and transmembrane forms and interacts with two high affinity receptors,
TNFR1 and TNFR2. TNFR1 has a death domain, which is a required for the recruitment of
proteins involved in apoptosis and is expressed on every cell type. TNFR2 is expressed on
immune, endothelial, and nerve cells [1]. TNF can have both local and systemic effects, due in
part to its ability to act on several different cell types [114]. TNF can induce various types of
signaling pathways, but one of the most studied pathways relevant to IBD is the NFκβ pathway
[11]. TNF activates NFκβ in a cell-type nonspecific manner, which often leads to the secretion of
more TNF, as well as IL-1 and IL-6. Increased activated NFκβ has been found in the
macrophages and epithelial cells of IBD patients [11]. Aside from apoptosis cascades; TNF can
also activate extracellular signal-related kinase (ERK), p38 mitogen-activated protein kinase
(p38MAPK), and cJUN N-terminal kinase (JNK) pathways. TNF has been shown to be integral
to homeostasis, as overexpression and under-expression has been linked to several disorders [27].
It is still used to treat some cancers [48], but overexpression due to uncontrolled NFκβ signaling
is linked to cancer [1]. TNF overexpression has been implicated in Alzheimer’s disease,
Parkinson’s disease, diabetes, and heart disease[1].

IBD is known to be linked to overexpression of TNF [109,209], and the treatment strategy
known as TNF blockade has been a moderately successful treatment strategy for IBD patients.
However, sustained TNF blockade can come with serious risks. TNF blockade may make
patients more susceptible to potentially fatal infections such as tuberculosis [34,136], as well as
increases risk of developing lymphoma and other malignancies. Moreover, some patients do not
respond to anti-TNF drugs, while others respond only for a short period [45,139,201]. Despite its
numerous limitations, anti-TNF therapy remains widely used as part of IBD treatments.
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1.3

The human gut microbiome

Studies have shown that the skin, gut, respiratory, and reproductive systems each have dynamic
bacterial populations that are sensitive to changes in the host environment and contribute to
physiological homeostasis [43,104]. The human gastrointestinal (GI) tract is comprised of
several niches with unique physical and chemical properties and is estimated to be populated
with approximately 1013 bacterial cells [98]. The oral cavity, stomach, small and large intestines
are sites of sequential digestion processes and are therefore populated by microbes with specific
roles in each step of the process.

The term ‘gut microbiome’ is generally used to describe the microbial communities of the large
intestine, or colon. The human large intestine is comprised of several sections; the ascending
colon (including the cecum), transverse colon, descending colon, and sigmoid colon. Inside the
large intestine, a double layer of mucus coats the entire surface. The inner layer, closest to the
epithelium, is considered to be largely sterile [133]. The outer layer provides a niche for
microbes to exchange molecules with the host, defend against infections, and compete for
resources. The outer later is renewed by continual shedding of the loose mucus into the lumen,
while replenishing itself with mucus from the inner layer [61]. The mucosal microbes may have
stronger influence over the intestinal immune system because of their proximity to the
epithelium. In the large intestine, water and minerals are absorbed from digested material, and
microbes break down previously undigested complex foods for energy. The remaining material
is excreted as fecal matter, which is widely used as a starting material for studies that seek to
characterize the bacterial communities of the colon. Feces are the favored sample for
microbiome studies due to the increased cost and decreased feasibility of mucosal sampling,
especially in humans.

The gut microbiome in healthy humans is highly individualized, with variations present even
within twin pairs [189]. However, all studied human microbiomes share some generalized
features. Of the 52 currently identifiable bacterial phyla, the human gut is dominated by only five
[196]. Members of the phyla Actinobacteria, Bacteroidetes, Firmicutes, Proteobacteria, and
Verrumicrobia comprise the majority of bacteria in the gut as identified by 16S rRNA gene
sequencing [98]. The human gut microbiome is colonized at birth through maternal and
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environmental exposures [170,260]. Studies have shown that breastfeeding seeds the neonatal
gut microbiota and selects for beneficial microbes that play a role in infant health and
development [170,187]. After a period of rapid structuring, the healthy human gut microbiome
stabilizes at approximately age 3 years, as infants ages 0-3 years have been shown to have
significantly higher individual variation than persons older than three years [260]. Studies have
shown that our gut bacterial diversity increases as we age but that the overall composition of the
gut microbiome in healthy individuals is stable throughout adulthood before shifting again in
persons aged 65 and older [207,260].
1.3.1

The gut microbiome is closely connected to the immune system

The implications of the co-evolved relationship between humans and our gut microbiota cannot
be overstated. Research has demonstrated that the microbial composition of the gut influences
the development and maturation of the innate and adaptive immune systems [153], which places
the gut microbiota in a key role in host defense. In the healthy gut, the immune system keeps
foreign microbial populations under control. Microbes are recognized by toll-like receptors and
nucleotide oligomerization domain (NOD) receptors: molecules that are localized to the gut
epithelial and immune cells [211,232]. These receptors monitor the microbial milieu, activating
an immune response when triggered by microbial stimuli. In parallel, the microbiota contributes
to immune system regulation by promoting T cell differentiation [257]. Studies have identified
specific microbes that are believed to play important regulatory roles. Clostridia have been
shown to down-regulate expression of Th1 and Th17 immune responses, as well as promote
expansion of regulatory T-cells (Tregs) [78]. Segmented filamentous bacteria (SFB) have been
shown to induce Th17 cell differentiation [75,76]. The literature provides clear rationale for the
continued study of how the gut microbiota interacts with the immune systems and the
implications for human health.
1.3.2

Gut microbes as regulators of homeostasis

Studies suggest that the combined activities and metabolic products of the gut microbiota, rather
than the effects of a single pathogenic organism, are the true mediators of intestinal homeostasis
[143]. The anaerobic microbes that inhabit the large intestine are responsible for fermenting
undigested dietary components into a wide range of metabolites. These metabolites normally
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include gases and organic acids, as well as enzymatic products and the result of anaerobic
respiration. A subset of these organic acids -- acetate, butyrate, and propionate-- are collectively
known as the short-chain fatty acids (SCFAs). SCFA’s have been shown to be involved in
maintaining host health [129,160,221]. Studies show that propionate and butyrate are produced
by the enteric bacteria, and several studies have associated the production of different SCFAs
with certain bacterial phyla [140,142,198]. The total fecal proportion of propionate was shown to
be correlated with the relative abundance of Bacteroidetes [208]. It has been reported that acetate
and lactate is used by microbes such as Eubacterium rectale and Anaerostipes spp. to produce
butyrate [141]. These types of exchanges work together to shape the gut ecosystem. SCFAs are
known influence the immune system. Acetate, butyrate, and propionate are absorbed in multiple
regions of the colon [20]. Butyrate and propionate are inhibitors of histone deacetylase (HDAC)
activity in colonocytes and immune cells, which leads to the down regulation of proinflammatory cytokines [35,47,73]. Propionate and butyrate have also been shown to induce
anti-inflammatory colonic T regulatory forkhead box protein p3 (FOXP3) positive cells [74,222].
Butyrate is known to be anti-inflammatory due to its inhibition of NFkB activation [261] .
Moreover, SCFAs regulate T cell differentiation as well as immune cell migration via G-protein
coupled receptor (GPCR) pathways [229]. Microbes and their products have an active role in the
immune system, metabolism, and even the physiology of the brain [52]. Therefore, disturbances
in the gut microbial ecosystem can have profound impact on the host.
1.3.3

The human gut microbiome in IBD

The gut immune system must maintain a delicate balance between surveillance for pathogenic
invaders and tolerance of normal microbial residents. Evidence suggests that during IBD, the
immune system fails to tolerate normal gut microbial communities [95,156,158]. There is a
wealth of evidence showing that the gut microbiomes of IBD patients also deviate from that of
healthy individuals. Generally, lower diversity is noted in both the fecal and mucosal
microbiomes of persons with IBD [69,130,151]. Changes in community composition have also
been linked to the presence of IBD. Increases in the relative abundance of Enterobacteriaceae,
Pasteurellaceae, Veillonellaceae, and Fusobacteriaceae have been associated with IBD [79]. In
contrast, certain members of Lachnospiraceae and Ruminococcaceae are more relatively
abundant in healthy individuals [146,236]. Alterations in the proportions of specific species,
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including known pathogens, have also been observed in IBD and are proposed to play a role in
disease course. Increased abundance of Shigella, Escherichia coli, C. difficile, and Klebsiella
pneumoniae have been seen in IBD [156]. Importantly, higher abundances of adherent invasive
E. coli (AIEC) has been found in the tissue of CD patients (more so than in the feces). Studies
evaluating the importance of diet have shown that individuals with Western diets are more
susceptible to AIEC infections, potentially linking diet to IBD susceptibility [2]. Fusobacterium
has also been identified as a potential pathogen, as certain invasive species have been found to be
increased in humans and mice with IBD, while other species are normally associated with the
healthy gut and oral microbiome [227]. Conversely, some taxa have been shown to promote
health. Faecalibacterium prausnitzii produces the SCFA butyrate, which is known for its antiinflammatory properties. F. prausnitzii has been shown to be reduced in both CD and UC
patients [31,190], and even to ameliorate inflammation when given to mice with TNBS colitis
[223]. Specific mechanisms behind the alterations of specific populations have also been
proposed. A recent study has implicated bacterial urease-mediated nitrogen flux in CD dysbiosis.
In this study, researchers ‘re-programmed’ the microbiota by reducing bacterial load and recolonizing mice with E. coli lacking urease. This study provided evidence for urease-mediated
dysbiosis and the authors suggest that limiting bacterial load before the administration of
probiotics may enhance probiotic effectiveness [179].

While there is evidence for specific impacts of certain microbes or groups of microbes in IBD, it
is important to maintain a community perspective when examining microbiome studies.
Microbes do not exist in a vacuum, and it is important to consider the ecological relationships at
play in each system studied. It is also important to consider other environmental factors that may
impact the gut microbiome, severity of IBD symptoms, and response to treatment.

1.4

Mouse models in IBD research

To unravel the relationships between the gut microbiome and IBD pathogenesis, mouse models
can be used in lieu of humans. Humans typically have high levels of inter-individual variation
that make it hard to uncover clear trends without very large sample sizes that can be cost-
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prohibitive. A majority of IBD animal studies are conducted using a mouse model of colitis, and
several models have been developed (reviewed: Mizoguchi [164]).
1.4.1

Mouse models of colitis

Briefly, cell-transfer, spontaneous, genetically engineered, and chemically-induced models have
all been developed to study specific mechanisms and phenotypes of IBD. The CD45RB cell
transfer model of colitis can be induced by transferring naïve CD4+ T cells from wild-type (WT)
mice into immunodeficient mice [193]. This model results in a Th1 inflammatory response,
marked by expression of TNF and IFNγ that resembles CD. Spontaneous colitis can also be
induced by ablation of IL-2, IL-10, or T-cell receptor α (TCRα) [123,166,206]. Still other
genetically engineered models have been developed by either knocking out or overexpressing
one of various targets that makes the mice susceptible to colitis induced by pathogens such as
Helicobacter pylori [178]. Selection of the most appropriate model is based primarily on the
study objectives, with consideration for cost and reproducibility. This work utilizes a chemically
induced colitis model. Chemically-induced models provide a relatively inexpensive, technically
simple way to study mechanisms of pathogenesis, potential therapeutics, and alterations in the
microbiome during colitis.
1.4.2

Chemically-induced models of colitis

There are three main chemically induced models; dextran sulfate sodium (DSS), 2,4,6
trinitrobenzene sulfonic acid (TNBS), and oxazolone. Acute and chronic DSS colitis can be
induced in mice by the addition of DSS to the drinking water. DSS is toxic to the colonic
epithelium and causes defects in mucosal barrier function, leading to acute inflammation. Mice
with DSS colitis exhibit weight loss, bloody stool, colonic ulcers, and a loss of colonic crypts
and goblet cells [37,116] . The DSS model has proven useful for studies examining the role of
neutrophils [51] , macrophages [194] , cytokines [50], and the inflammasome [55,262] in tissue
injury and repair [33,101]. It has also been widely used to study the development of colitisassociated cancer when combined with the carcinogen azoxymethane [87]. In the context of IBD,
DSS colitis produces a Th2 response that most resembles UC [37]. Chronic DSS colitis can be
induced by cyclical administration of DSS at a low dosage. The resulting inflammation is
dominated by T-cells and macrophages[37].
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Oxazolone is a haptenating agent that modifies proteins on the colonic epithelium and renders
them immunogenic. Acute colitis is induced with a single intrarectal injection of oxazolone.
Chronic colitis can be induced by pre-sensitizing the mice to Oxazolone by painting it onto the
skin before intrarectal injection[96]. Oxazolone elicits a Th2 driven inflammatory response,
marked by increased production of IL-4 and IL-5, IL-13, and IL-9[96] as well as activation of
Natural killer T- cells (NKT)[184]. Oxazolone treatment also results in colonic ulceration and
loss of epithelial cells, and therefore most closely resembles human UC [21,144] .
1.4.2.1 TNBS Colitis
The third chemically induced colitis model is the TNBS model. The TNBS model was
introduced in 1989 and has been widely used to study the pathology of CD, as well as test the
effects of potential anti-inflammatory compounds on colitis in mice and rats. TNBS colitis is
induced by intra-rectal administration of TNBS mixed with ethanol. Several characteristics of the
resulting inflammation are relevant to CD. TNBS induces colitis by haptenating colon tissue
proteins, which causes them to elicit an immune response. The resulting immune response is
driven by Th1 and Th17 type inflammation, just as in human CD. Secretion of cytokines IL-12,
IL-23, TNF, and IL-17 is also characteristic of TNBS colitis and CD. TNBS colitis has also been
shown to involve NOD2, which has been identified as a CD susceptibility gene. Moreover,
TNBS administration has been shown to result in transmural inflammation that is similar to the
lesions that occur in human CD [9].

Histopathologically, TNBS treatment results in mucosal edema, loss of glands and goblet cells,
and crypt distortion in affected colon tissue. Acute TNBS induced inflammation involves
infiltration of leukocytes and erythrocytes into the mucosa and submucosa. As the inflammation
becomes chronic, infiltration of neutrophils, macrophages, and lymphocytes as well as the
fibroblasts and granuloma can be seen. Phenotypically, mice and rats with TNBS colitis typically
have unformed stool and/or bloody diarrhea, accompanied by weight loss, lethargy and extreme
wasting disease in some cases [9]. In severe cases, rectal prolapse may occur [9]. Because of its
relevance to CD, the TNBS colitis model is considered useful for basic science studies seeking to
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understand the CD immune response or investigate the roles of genetic interventions, the gut
microbiome, or potential benefits of various compounds on CD-like colitis.

While the TNBS model, like all animal models, has its limitations (varying symptom severity
depending on animal type and strain, no inflammation in other areas of the GI tract, not relevant
to CD in etiology); the strengths of this model include its low cost, reproducibility, a relatively
simple technical protocol, and an immune response similar to human CD.
In addition to its immunological features, the TNBS colitis model, like other colitis models, can
be used to investigate the role of the microbiome in the context of intestinal inflammation.
1.4.3

The relevance of the mouse gut microbiome to the human gut microbiome

The mouse microbiome is like the human microbiome in that it is composed primarily of taxa
from two phyla, Bacteroidetes and Firmicutes. However, there are differences at deeper
taxonomic levels. A meta-analysis of healthy human and healthy mouse microbiota data found
approximately 80 shared genera, but there were differences in abundance. Humans had higher
abundances of Prevotella, Faecalibacterium, and Ruminococcus, whereas mice had higher
abundances of Turicibacter, Lactobacillus, and Alistipes [178]. Additionally, Clostridium,
Bacteroides, and Blautia were found at similar relative abundances in mice and humans. Overall,
humans have displayed high inter-individual variation in the microbiota, which requires large
sample sizes in human studies that seek to identify dysbiosis-associated organisms. An important
advantage to using mice for microbiome studies is that there tends to be less individual variation.
This reduced variation may be the result of controlled laboratory environments and the similar
genetics of inbred mice, as a comparison of wild mice and laboratory mice found higher
individual variation in wild mice [135]. In the context of IBD, the mouse microbiome does share
some features with the human microbiome. Both humans and mice display reduced microbial
diversity, as well as increases in Enterobacteriaceae, Bacteroidaceae, and Ruminococcaceae
[16,148,256]. There have also been differences observed. A reduction in Akkermansia was
observed in human UC [245], but an increase was observed in the mouse DSS colitis model [16].
Additionally, changes in microbes belonging to TM7 and Deferribacteriaceae have only been
seen in mouse models of IBD [172]. Despite the difficulty in directly translating mouse
microbiome data back to humans, there remains a consensus that the mouse provides a relevant
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system for studying the microbiome. Mice can be used for invasive experiments, as well as to
test various interventions. Knockout mice allow for targeted studies on the effect of individual
components on the gut microbiota. Laboratory mice also have a homogenous genetic
background, which reduces individual variation. Mouse models of IBD remain useful tools to
study the interactions between inflammation and the gut microbiome.
1.4.4

The interface of TNF, the gut microbiome, and IBD

Our lab is interested in the gut microbiome as it pertains to CD. Data from microbiome studies
show differences in the microbiomes of CD patients when compared to UC patients. A study by
Pascal et.al revealed that the gut microbiomes of UC patients were more similar to healthy
individuals than to CD patients [190]. Moreover, the microbiome of UC patients, similar to
healthy individuals, has been shown to display less fluctuation over time than CD patients [89].
Additionally, the effect of TNF on the gut microbiome is not completely understood. Differences
in the gut microbiomes of patients has been suggested to contribute to variations in response to
anti-TNF therapy [109]. It has been shown that germ-free mice genetically manipulated to
overexpress TNF remain free of inflammation, while mice with a conventional gut microbiome
who overexpress TNF developed spontaneous colitis [214].

In a previous study, our lab utilized the TNBS model to investigate the roles of TNF (via
homozygous deletion of Tnf gene) and the gut microbiota in mice during acute colitis [108]. We
showed that mice with genetic depletion of TNF (Tnf--/- mice), have less severe acute TNBS
colitis along with significantly different gut microbiomes compared to mice with unaltered TNF
expression [108]. Differences in the microbiomes were seen even before acute colitis induction,
indicating that Tnf has an impact on the gut microbiome even in the absence of inflammation.
Tnf-/- mice had significantly lower alpha diversity than WT mice. They also had significantly
different proportions of certain taxa. Relative abundances of Turicibacter, unclassified
Clostridiaceae, and unclassified Ruminococcaceae were significantly lower in Tnf-/- mice before
colitis. After colitis, we again observed significant differences in taxa proportions in each
genotype. Additionally, we found that the lack of TNF was associated with less ulceration and
concluded that the strongest factor contributing to the alterations in the microbiome and colitis
severity was TNF production.
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Despite the discovery of a clear impact of TNF ablation on the microbiome, the data also
presented some interesting challenges. Microbiome analysis revealed high levels of unexplained
variation in the data. The acute colitis experiments were repeated several times, and despite
consistent histological results, experiment seemed to be having a significant impact the
microbiome. This consistent finding formed the basis for my investigation into environmental
factors that impact the mouse gut microbiome in a laboratory setting.
1.4.5

Factors affecting the gut microbiome in animal studies

In microbiome studies, laboratory mice are valued in part for their genetic similarity, which
theoretically reduces the inter-individual variation and allows for more robust hypothesis testing.
Ease of genetic modification has allowed for the creation of unique phenotypes to study a myriad
of biological and physiological conditions. However, these differences in genetic backgrounds
can be linked to different susceptibilities as well [199]. Specific data on how the microbiome
differs among mouse strains is limited. However, in the context of IBD, we do know that
different mouse strains experience variable susceptibility to colitis induction methods. Studies
show variations in colitis severity based on mouse strain. The two most commonly used mouse
genetic backgrounds are BALB/c and C57BL/6J. In the dextran sulfate sodium (DSS) colitis
model, C57BL/6J mice develop chronic colitis after repeated exposure, whereas BALB/c mice
have only an acute colitis that resolves after cessation of DSS treatment [161]. Conversely, B6
mice are relatively resistant to TNBS colitis whereas BALB/c mice are highly susceptible. The
susceptibility differences in the TNBS model have been proposed to stem from genetically
determined differences in ability to produce IL-12 in response to bacterial stimulation. High IL12 production was associated with susceptibility, whereas low IL-12 production was associated
with resistance [25]. Specific loci, such as H. hepaticus- induced colitis and associated cancer
susceptibility(Hiccs) [24] and cytokine-deficiency induced colitis susceptibility(Cdcs1) [19],
have been identified that are thought to contribute to colitis susceptibility by modifying the
responsiveness of macrophages to cytokine signals [60]. More work is needed to understand how
these loci and their associated effects on the immune system may impact the gut microbiome.

16
In addition to genetics, sex has also been recently identified as a potential contributor to
differences in the gut microbiome in both mice and humans. Whereas several human diseases
exhibit sexual dimorphism, such as cardiovascular disease, asthma, systemic lupus
erythematosus, and type I diabetes [181]; studies failed to come to a consensus on whether sex
impacts the microbiome [104,128]. However, a large study comprised of 689 mice from 89
strains identified several significantly different taxa in the gut microbiomes of males and females
[185]. When controlling for strain, males had higher relative abundances of Allobaculum,
Aneroplasma, and Erwinia, while females had higher relative abundances of Clostridiaceae
SMB55, Dorea, Coprococcus, and Ruminococcus. Moreover, the data showed that the
microbiomes were more similar within strains than between strains. This means that strain
effects may overshadow sex effects in other mouse studies (and other host variables in human
studies), and that the impact of the gut microbiome in each sex to other factors could be strain
dependent. This study also provided evidence, in agreement with other studies that sex hormones
influence microbiota composition, and even that the response of the gut microbiota to diet may
be sex-specific [22,29]. Therefore, examining the impact of sex on the gut microbiome in the
mouse models of disease is critical to a full understanding of the pathogenesis and the
contribution of the gut microbiome to IBD.

1.5

Summary

Crohn’s disease and ulcerative colitis are chronic diseases with no current cure that greatly
reduce quality of life while increasing the risk of developing colorectal cancer. The existing
treatments are not universally effective and can have dangerous side effects. Animal models of
colitis have provided invaluable evidence that has led to the development of treatments and a
better understanding of the inflammatory mechanisms behind these conditions. Crohn’s disease
and UC are distinct phenotypes of IBD, and a complete understanding of disease processes that
could lead to curative therapies will require careful examination of immune and microbial
contributions to each phenotype. Current treatments may work well in UC, but then not at all in
CD, and vice versa. It is known that the microbiome plays an important, yet incompletely
understood role in the pathogenesis of both UC and CD. Straightforward replacement of a
‘healthy’ fecal microbiome shows promise in UC patients, but not CD patients. Moreover, even
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anti-TNF therapy, a widely used treatment option for IBD patients, shows varying success. The
existing literature clearly points to a relationship between TNF and the gut microbiome that may
impact colitis severity and even response to treatment. However, this relationship is not well
understood.

The overall objective of the lab is to understand the impact of the gut microbiome in Crohn’slike colitis. As previously mentioned, our lab investigated the impact of TNF on the microbiota
in acute TNBS colitis. We found that Tnf-/- mice had less severe colitis than WT mice, and that
Tnf-/- mice had microbiomes that were distinct from WT mice [108]. However, we also observed
high variability in our microbiome data across experiments. Therefore, the overall objective of
this project was to determine how TNF and host variables impact the mouse gut microbiome
during colitis, I hypothesized that host factors such as sex and age contribute to variation in the
microbiota which could potentially impact disease outcome. This is especially important
considering the inconsistent reports in the literature on whether sex impacts the microbiome.

The phenotypes of IBD, CD and UC, are chronic diseases, and it is important to investigate the
microbiome in chronic TNBS colitis to determine the effect of long-term inflammation.
Additionally, the microbiomes of different regions of the GI tract have been shown to be distinct,
with the mucosal microbiome often showing more distinct IBD associated changes than the fecal
microbiome in humans. However, unlike the human colon, the mouse colon is not segmented
and is not the site of microbial fermentation that produces beneficial SCFAs [178]. Microbial
fermentation occurs in the cecum of mice. Perhaps the cecal microbiome of mice after colitis
would be more applicable to the dysbiosis seen in human IBD. Conversely, since the TNBS
colitis is chemically induced by direct injection into the rectum, the fecal microbiome could
likely be the most directly affected by TNBS treatment. My second hypothesis was that Tnf-/mice will have less severe chronic TNBS colitis and a distinct microbiome compared to WT
mice, and that sex impacts both the microbiome and colitis severity of both genotypes.
Additionally, the fecal, cecal, and mucus microbiomes of mice after colitis will be distinct, and
colitis severity will be most closely associated with the fecal microbiome.
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As microbiome data from mouse studies accumulate, it has become clear that differences in
disease behavior among mice of different strains limit the comparability of results across studies.
Laboratory mice can be derived on several genetic backgrounds, and researchers can choose
appropriate mouse models based on their disease of interest, cost-effectiveness, and technical
difficulty. My final hypothesis was that mouse strain impacts the fecal microbiome.
In summary, my hypotheses are as follows:
1) Age, sex, and TNF affect the fecal microbiome of mice, and impact the severity of
acute TNBS colitis.
2) TNF, sex and disease severity impact the microbiome in chronic TNBS colitis and
the composition of the fecal microbiome will closely correlate with colitis severity.
3) The strain of mouse impacts the fecal microbiome.
To test my hypotheses, I employ a variety of analyses. The TNBS model of colitis is used to
induce acute and chronic colitis in WT mice and Tnf-/- mice. 16S rRNA gene sequencing is
performed on samples from each genotype of mouse, and sequencing analysis is used to describe
the microbial community composition, diversity, and identify differentially abundant microbes.

This work provides insight into the impact of TNF on the gut microbiome during TNBS colitis,
as well as identifies several taxa that are associated with mouse host factors and the spatial
geography of the mouse gut. Moreover, it highlights the importance of meticulous experimental
design in animal studies to reducing the effect of confounding factors that are hard to control in
human studies, such as diet, age, and housing. It provides a foundation and recommendations for
future studies that seek to further unravel the complex interactions between the microbiome and
the immune system in the context of inflammation.
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CHAPTER 2.
THE IMPACT OF AGE, SEX, AND TNF ON THE GUT
MICROBIOTA IN A MOUSE MODEL OF COLITIS

Portions of this chapter reused with permission for non-commercial use from the Journal of
Experimental and Molecular Pathology. A.J. Kozik, C.H. Nakatsu, H. Chun, Y.L. Jones-Hall,
Age, sex, and TNF associated differences in the gut microbiota of mice and their impact on acute
TNBS
colitis,
Exp.
Mol.
Pathol.
103
(2017)
311–319
https://doi.org/10.1016/j.yexmp.2017.11.014.
2.1

Introduction

Crohn’s disease (CD) is a subtype of Inflammatory Bowel Disease (IBD) that is characterized by
recurring episodes of inflammation along any part of the gastrointestinal tract. Studies have
linked alterations in the composition of the gut microbiota with IBD [157]. Mouse models are
often used to investigate relationships between the microbiota and the inflammatory process.
Mice exhibit differences in gut microbiomes associated with inflammation in various colitis
models [81] that may lead to a better understanding of the role of certain microbes in human IBD.

Despite the benefits that mouse models provide, such as allowing for more invasive studies,
variable endpoints, and reducing individual variation in the microbiota that is seen in humans;
descriptions of IBD-associated differences in the gut microbiome have been inconsistent in
mouse models. In laboratory mice, environmental variables such as housing conditions, facility
of origin, variations in handling, time of sampling, antibiotic use, and diet have all been shown to
contribute to differences in the gut microbiota [15,22,102,168,235,247]. Additionally, marked
differences in the microbiota have been described in mice with different genetic backgrounds
[30,102]. For example, the microbiota of mice with a BL6J background have been shown to have
high intra-strain variability, whereas mice of CH3RI background have low intra-strain variability
[71].

While it seems obvious that genetic background would impact the microbiome, it is possible that
the impact of other characteristics, such as mouse age, on the microbiome may be
underestimated. It is well documented in human studies that the gut microbial community
structure changes as humans age [99,152,260], with rapid changes observed until 3 years of age,
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followed by relative stability at the phylum level until geriatric associated changes appear [99].
Similar to humans, research indicates the gut microbiota of mice changes as they age [68], but
most of these studies pertain to mice that are older than 6 months of age. In laboratory mice
weaning occurs at approximately 3 of age and changes in the gut microbiota occur during this
transition, presumably related to diet changes from milk to solid food [215]. Additional data
pertaining to changes in the gut microbiota in mice before 6 months of age are limited. As many
mouse studies utilize mice between the wide ranges of 6 to 12 weeks of age, it is important to
understand age-related differences in the microbiome that may influence experimental outcomes.

Another potentially underestimated characteristic is mouse sex. Until recently, relatively few
studies had investigated sex-differences in the mouse microbiota, and the existing data reports
minor, if any, differences [30,241]. A study by Bolnick et al. that considered sex in conjunction
with environmental variables revealed sex-specific effects in the interactions of diet and the gut
microbiota in mice and humans [22]. Motivated by the scarcity of pertinent studies, our goal was
to characterize sex related differences in the gut microbiota of mice before and after acute TNBS
colitis. I compared microbiome data from experiments utilizing male and female B6.129 mice
from two age groups, 4-5 weeks of age and 6-7 weeks of age.

Tumor necrosis factor (TNF) is a pleiotropic cytokine secreted by several types of immune cells.
TNF has been shown to be elevated in patients with CD [93], and as a master regulator of
inflammation, it is the target for several widely used inhibitor therapies in IBD treatment [210].
TNF has been shown to have both pro and anti-inflammatory effects in the body [155,230].
While TNF is known to be a major player in the inflammatory cascade, the nature of its
interactions with the gut microbiota has yet to be fully elucidated. In our study, mice with
deletion of the Tnf gene (Tnf-/-) were used to investigate the effect of TNF on the microbiome and
acute TNBS colitis. Previous studies in our lab using female mice revealed that ablation of the
Tnf gene resulted in mice with a microbiota that was distinctly different from that of wild-type
(WT) mice [108]. In this study, I expanded our analysis to examine the effect of TNF ablation on
male mice and their gut microbiota. I therefore hypothesized that sex, age, and TNF all
contribute to differences in the gut microbiome and that these differences in in the microbiome
will correlate with differential degrees of acute TNBS colitis severity.
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2.2
2.2.1

Methods
Mice

All animal experiments were approved by the Purdue Animal Care and Use Committee. Male
and female B6.129S mice with a homozygous deletion of the Tnf gene- (B6;129S6-Tnftm1Gkl/J;
Tnf-/- mice) and control male and female B6.129S mice (B6129SF2/J; WT mice) were obtained
from the Jackson Laboratory (Bar Harbor, ME) and subsequently bred and housed at Purdue
University. Mice were housed in specific pathogen free conditions and maintained on 12hr
light/dark cycles with free access to food and water. Mice were fed with 2018s mouse chow
(Envigo). Mice were caged separately by sex, genotype (Tnf-/- vs WT) and treatment (TNBS vs
SHAM). Littermates were used for all experiments. Four to seven-week old mice were used for
experiments. All ages reported are based on the ages of the mice at the beginning of each
experiment. Mice of both sexes were used for all age analyses. Mice are described in the figures
and text by their assigned treatment group (TNBS or SHAM), however all mice at day 0 are
‘untreated’ and so mice from the TNBS groups at day 0 are referred to as ‘pre-colitis’.
2.2.2

Acute Colitis

Power calculation determined that at least five mice per treatment group were needed. The
experiments were performed three times with 5-8 mice in each treatment group. Colitis was
induced as previously described [108,254]. Sensitization solutions for the TNBS treatment group
(acetone and olive oil mixed in a 4:1 volume; four volumes of acetone/olive oil solution were
mixed with 1 volume of 5% TNBS (Sigma-Aldrich) solution), and SHAM treatment group
(acetone and olive oil mixed in a 4:1 volume) were prepared. On day 0, 100 μl of TNBS
sensitization solution or SHAM solution was painted on a shaved field of skin between the
shoulders of anesthetized mice. The intra-rectal (IR) solutions were prepared as follows: TNBS
(1 volume of 5% w/v TNBS solution mixed with 1 volume of absolute ethanol), SHAM (50%
ethanol in PBS). On day 7, 100 μl of the TNBS or SHAM IR solution was slowly instilled into
the lumen of the colon of anesthetized mice. Three days post IR injection necropsy was
performed and tissues were harvested. Mice were euthanized by an overdose of CO2 followed by
cervical dislocation. Fecal samples for microbial community analysis were collected and snap
frozen on days 0 and 10 and stored at -80°C until analyzed.

22
2.2.3

Histological Assessment of Colitis

After removal, colons were opened and washed with PBS. Four centimeters of one-half of the
distal colon was fixed in 10% buffered formalin for histological examination. The remaining
colon was snap frozen in liquid nitrogen and stored at -80°C. Formalin fixed sections of colonic
tissues were embedded in paraffin and 6-μm sections were stained with hematoxylin and eosin
(H&E). The sections were evaluated by an experienced veterinary pathologist, blinded to the
treatment groups. Colitis was assessed semi-quantitatively as we have described previously [108].
Briefly, colitis severity was scored as none or 1-3 if present. Extent of inflammatory infiltrate
was judged as focal, multifocal, or diffuse 1-3. Erosion and necrosis were both scored as none or
1-3, if present. Total disease score ranges from 0 to a maximum 12 points based upon the sum of
each assigned criterion.
2.2.4

DNA Extraction and Sequencing

Total DNA was extracted from each fecal sample (38 mg on average) using the FastDNA Spin
kit for soil (MP Biomedicals) per the manufacturer’s instructions. DNA quality was assessed
using a NanoDrop 1000 spectrometry (260/280 ratio) as well as gel electrophoresis. DNA
concentration was determined using a NanoDrop 3300 (Thermo Scientific, Wilmington, DE)
fluorospectrometer. Fecal DNA from day 0 and day 10 (necropsy) was sequenced using MiSeq
Illumina 2x 250 paired end sequencing. Primers that amplify the V3-V4 region of the 16S rRNA
gene (343-forward TAC GGR AGG CAG CAG and 804-reverse CTA CCR GGG TAT CTA
ATC C primers) were used. Samples were tagged with a combination of 8-bp forward and 8-bp
reverse primers per the manufacturers protocol (Illumina). PCR was performed using Q5 High
Fidelity DNA Polymerase (New England Biolabs). The Agencourt AMPure XP kit (Beckman
Coulter) was used to remove unincorporated primers and nucleotides from PCR amplicons. The
resulting purified amplicons were quantified by fluorometry with the Quantifluor dsDNA Assay
Kit (Promega). Equimolar quantities of amplicons from each sample were combined and sent to
the Purdue Genomics facilities for sequencing using a MiSeq instrument (Illumina).
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2.2.5

Sequence Analysis

Panda software [154] was used to merge high-quality reads after the removal of primer tags and
low quality sequence reads. Sequences were analyzed using the QIIME pipeline version 1.9.1
[32]. The “pick open reference OTU” option with default variables and the Greengenes data set
(version 13_8) were used to assign taxonomy to the representative OTU sequences [159]. All
subsequent comparisons were performed using equivalent numbers of sequence reads (based on
the lowest number of sequences obtained from a single sample) per sample. Good’s coverage
provided an estimate of sequence coverage of the communities used in these analyses. Rarefied
analyses of alpha diversity indices (Chao1, observed OTUs, Shannon) were calculated to
compare microbiota community diversity within each sample. Beta diversity comparisons among
communities were made using the phylogenetic distances unweighted and weighted UniFrac
[90]as well as non-phylogenetic distance analysis using Bray Curtis distances. For age analysis,
mice were grouped according to age at day 0. Male and female mice are combined for all age
analyses. Mice aged 4-5 weeks (31-36 days old), and 6-7 weeks (43-48 days old). Mice are
placed in an age range by their age at day 0 and described in this age range throughout the
manuscript.
2.2.6

Statistics

Statistical differences in histological scores were found with the nonparametric Mann-Whitney U
test. All data in bar graphs or dot plot formats are expressed as mean ± S.E.M. Statistical
significance is p <0.05. For the microbiome analyses, Kruskal-Wallis analysis (non-parametric
equivalent to ANOVA) was used for an overall comparison of average proportions of each taxa
level (phyla, class, order, family and genera) in mice fecal samples between age groups. Linear
Discriminant Analysis Effect Size (LEfSe) [218] was used to identify taxa that contribute
significantly to the differences in the microbiomes between experimental groups. LEfSe
identifies taxonomic features of a dataset that can differentiate between different groups of
interest. It first applies the Kruskal Wallis sum rank test to detect taxa with differential
abundances between the selected groups. Then, consistency is tested by pairwise Wilcoxon ranksum test. Finally, linear discriminant analysis (LDA) is used to estimate the effect size of each
differentially abundant taxon. Alpha was set to 0.05 and ‘all-against-all’ class comparison
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method was used. Wilcoxon test was also used to compare day 0 and day 10 samples within
treatments. All basic statistics were performed using GraphPad Prism version 6.00 for Windows
(GraphPad Software, La Jolla California USA).

Significant differences in beta diversity

(weighted and unweighted UniFrac, Bray-Curtis distances) among communities were determined
using PERMANOVA (a non-parametric multivariate statistic) [7]. To determine whether
significant differences could be due to dispersion, PERMDISP (permutational analysis of
multivariate dispersions) [6] was used. Both programs are available in the QIIME pipeline.
Canonical correspondence analysis (CCA) [26] in the R project (packages: vegan [54], MASS
[242], and vegan3d[183]; http://www.R-project.org/) was used to determine associations
between mouse sex, mouse age, mouse genotype, colitis scores and taxon relative abundance
among communities in each day-10 fecal sample. A permutation based Monte Carlo test was
used to identify significant correlations.

2.3
2.3.1

Results
Significant variation in the microbiome by experiment

Analysis of 33,200 sequences per sample revealed significant differences in beta-diversity
associated with experiment (Figure 2.1). Principal Coordinate Analysis (PCoA) of the Bray
Curtis metric reveals experiment COL-006 clusters away from the other three experiments
(PERMANOVA p<0.01). Separation can be seen on PC1, which explains 23.17% of the total
variation. The large variation introduced by COL-006 experiments concealed the impact of other
factors on the microbiome in the other three experiments. Therefore, data from COL-006 was
excluded from all subsequent analyses.
2.3.2

Female WT mice and Tnf-/- mice of both sexes have less colitis than male WT mice

Histological evaluation of disease severity indicated that female WT TNBS mice, (Figure 2.2B)
as well as male and female TNBS Tnf-/- mice, (Figure 2.2C-D) had less severe colitis than male
WT TNBS treated mice (Figure 2.2A). There were no significant differences in colitis between
male and female TNBS treated Tnf-/- mice. All TNBS treated groups except female Tnf-/- showed
significantly more colitis than non-TNBS treated controls (data not shown). Average colitis
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scores of control mice were WT males (3.0 ± 0.00); WT females (3.4 ± 0.47); Tnf-/- males (4.0 ±
0.00); Tnf-/- 6-7 females (2.9 ± 0.27).
2.3.3

Sex contributes to differences in the fecal microbiome pre-colitis

Comparisons of the rarefied 40,825 sequences from each sample at day 0 indicated that there
were significant differences in microbial diversity. Chao1, a within sample alpha diversity
estimate of species richness, indicated that males have significantly less species richness (p
=0.05) than females. (Figure 2.3A). Alternative alpha diversity metrics (e.g. observed operational
taxonomic unit (OTUs) confirmed these results. I computed the Shannon diversity metric, which
considers species evenness as well as richness, and found this value also lower in males than
females (p<0.05, not shown). I also measured beta diversity (Bray Curtis, weighted UniFrac,
unweighted UniFrac), which compares diversity among samples. Principal coordinate analysis
(PCoA) is used to visualize dissimilarities in a dataset (Figure 3B). In the plot, the axes, or
principal coordinates (PCs) represent separation gradients that account for the variability in the
data. PCoA of the Bray Curtis metric shows separation of communities by genotype on PC1, and
explains 29.11% of the variation in beta diversity. Sex separated on PC2, explaining 15.47% of
the variation in the beta diversity. PERMDISP confirmed that this significance was not simply
due to dispersion differences. All other beta diversity indices tested (weighted UniFrac,
unweighted UniFrac) showed similar trends.

Linear Discriminant Analysis Effect Size (LEfSe) analysis was used to identify the taxa that
significantly differed in male and female mice. LEfSe analysis identifies taxa in a dataset that
distinguish microbial communities from one another. In WT mice, the relative abundances of
Ruminococcaceae, Ruminococcus, and Anaerostipes were significantly higher in males and
Peptostreptococcaceae higher in female mice (Figure 2.3C). Adlercreutzia, Coriobacteria, and
Streptococcus, were proportionally more abundant in male Tnf-/- mice than in female Tnf-/- mice.
(Figure 2.3D).
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2.3.4

Alterations in the fecal microbial composition of Male and Female Mice after TNBS
colitis

LEfSe revealed taxa differences associated with sex, as well as colitis severity in WT mice. Male
WT mice had greater proportions of Planococcaceae, Bacillales, and members of the phylum
Proteobacteria. Female WT mice had greater relative proportions of Peptostreptococcaceae,
Clostridiaceae, and Turicibacter (Figure 2.4).
2.3.5

Age contributes to differences in colitis severity and the gut microbiome composition of
WT and Tnf-/- mice

To evaluate the impact of age on the microbiome composition and colitis severity in our study, I
compared disease severity among two closely aged groups. Colitis severity was significantly
lower in WT mice aged 4-5 weeks as compared to mice aged 6-7 weeks (Figure 2.5). Colitis
severity was also significantly lower in Tnf-/- mice aged 4-5 weeks than in mice aged 6-7 weeks
(Figure 5). Average colitis scores of control mice were WT 4-5 weeks (2.8 ± 0.89); WT 6-7
weeks (4.0 ± 0.89); Tnf-/- 4-5 weeks (3.4± 0.40); Tnf-/- 6-7 weeks (2.4 ±0 .24). All groups except
4-5-week Tnf-/- mice exhibited more severe colitis than controls.
There were also differences in the fecal microbiome between age groups in both WT and Tnf-/mice, pre- and post-colitis. The taxa that distinguish the 6-7-week-old WT microbiome from the
4-5-week-old microbiome were identified as Clostridiales, Firmicutes, and Butyrivibrio. The
most significant feature in 4-5-week old WT mice pre-colitis was the presence of Lactobacillus
(Figure2. 6A-B). Lactobacillus was also the taxon with the largest effect size post-colitis in 4-5week-old WT mice (Figure 2.6C-D). Bacteroidetes, Bacteroidales and Unclassified Bacteroidales
S24-7 also have large effect sizes, just lower than Lactobacillus in 4-5-week-old WT mice precolitis (Figure 2.6A-B), but none of these groups are shown to be significant features post-colitis.
Conversely, Burkholderiales is identified as a significant taxon in 4-5-week-old mice post-colitis,
but not pre-colitis (Figure 2.6C-D).

LEfSe analysis also revealed taxa that distinguished 4-5-week-old and 6-7-week-old Tnf
from one another. 4-5-week-old Tnf

-/-

-/-

mice

mice pre-colitis had higher relative proportions of
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Sporosarcina, Anaerostipes, and Bacilli (Fig 2.7A-B). Six-7-week-old Tnf -/- mice pre-colitis had
higher relative proportions of Clostridiales, Lachnospiraceae and Anaeroplasma. In Tnf-/- mice
post-colitis, 4-5-week-old mice had higher relative proportions of Lachnospiraceae,
Ruminococcus, and Clostridiaceae 02d06 than did 6-7-week-old mice. Whereas 6-7-week-old
mice had more abundant Bacilli, and Clostridium (Fig 2.7C) than did 4-5-week-old mice.
2.3.6

Canonical Correspondence Analysis confirms TNF, Sex, and Age as significant factors
contributing to differences in the fecal microbiome.

Canonical Correspondence Analysis (CCA) is a constrained ordination method used to infer
species-environment relationships. I performed CCA on the relative taxon abundances at day 10
(‘post-colitis’). The CCA model indicated that variation in species abundance was significantly
correlated with mouse age, sex, colitis score, and genotype (p=0.003) (Figure 2.8). Our CCA plot
shows a vector (arrow) that is nearly parallel to axis 1, which indicates a strong correlation
between this axis and mouse sex. Mouse age shows a strong correlation with axis 3. The relative
length of the vectors indicates their importance in our model. In our study, the most important
variables were shown to be sex, age, genotype, and colitis score, respectively. The angles
between each pair of environmental vectors indicate the correlations between the variables. Here
I observe a strong correlation between colitis score and genotype, as well as colitis score and age.
Axes 1,2, and 3 explain 51.0%, 23.5%, and 19.6% of the total constrained variation. The results
of the CCA revealed that together these three variables explain 94.1% of the total constrained
variation.

2.4

Discussion

Determining the specific role of gut microbes in CD is far from straightforward due to variability
of the gut microbiome between individual humans and animals. Despite the known contributions
of variables such as diet and housing facility to the mouse gut microbiome, the specific impacts
of mouse age and sex on the microbiome have been poorly described. I present here evidence for
sex, age and TNF associated differences in the B6.129S mouse gut microbiome, and suggest that
these some of these differences correlate with the severity of colitis.
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We observed the most severe colitis in male WT mice and these mice also had a higher relative
proportion of Alphaproteobacteria, and other members of the phylum Proteobacteria, than WT
female mice. This data supports a relationship between Proteobacteria and colitis severity, which
has also been observed in humans [264]. Increases in Proteobacteria in humans have been
proposed as a diagnostic signature of Crohn’s Disease (CD) [264]. While male mice have also
been reported to have more severe dextran sodium sulfate (DSS) induced colitis[28], no other
TNBS colitis studies have reported sex differences, to the authors’ knowledge. Although the
DSS colitis mouse model is widely used, DSS colitis has a mixed immunopathologic profile that
mimics features of both CD and ulcerative colitis, whereas the TNBS colitis model is more
directly applicable to CD [9,195]. Our data suggest that the acute TNBS colitis model in mice is
also useful for studying the impact of sex on colitis. The literature fails to provide a consensus on
the sex-bias of IBD in humans. Some studies have found that women are slightly more likely to
develop IBD than men, while others have found no evidence of sex bias [263]. The cause for
these supposed sex-differences are currently thought to be hormone related as male and female
immune systems respond differently to acute disease [62,80,119,239,244]. Sex may also be
interacting with other environmental factors to influence an individual’s risk of IBD
development. Mouse studies that consider sex effects in the microbiota using other colitis
models could provide insight into how sex may impact colitis response.

WT female mice had significantly more abundant Turicibacter and Unclassified Clostridiaceae
than males post colitis. Turicibacter is a genus of bacteria that has been commonly reported in
the mouse gut microbiome [178]. Previous studies from our lab also highlighted significant
differences in Turicibacter relative abundance, post colitis in WT female mice, as compared to
pre colitis [108]. Although there is limited data on its role in IBD in humans, it has been shown
to be decreased in CD patients [249]. Members of the family Clostridiaceae have been shown to
be involved in bile acid modification, and is negatively correlated with CD [125]. Concordantly,
WT female mice in our study had less severe colitis and more abundant Clostridiaceae. Notably,
however, Clostridiaceae has been associated with health as well as colitis [213,255], which
highlights the need for more in-depth studies of the colitis associated microbiota at lower
taxonomic levels.
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We have previously shown in studies using female mice that Tnf-/- mice have less severe acute
TNBS colitis than WT mice [108]. This study confirmed those conclusions, as well, I further
examined the microbiota of Tnf-/- mice to determine if there were sex differences like those seen
in WT mice. Pre-colitis, Tnf-/- males had higher proportions of Coriobacteriaceae and Klebsiella
(a genus in the family Enterobacteriaceae), both groups that are associated with IBD in humans
[38,110,197,253] but did not correlate with colitis severity in our study. One theory, is that these
groups are more abundant in the absence of TNF. More experimental data is needed to
investigate this; however. The most significantly differentiating taxa in Tnf-/- male mice postcolitis was the presence of Klebsiella. As stated previously, Klebsiella has been linked to
pathogenesis in CD [197], and the presence of Enterobacteriaceae, and the absence of
Anaerostipes has been reported as significant features of human CD [169,190]. The presence of
these colitis-associated microbes in Tnf-/- male mice suggests that the absence TNF expression
may facilitate their growth. Further investigation into how the microbiome shifts as colitis
progresses could help determine if the changes in proportions of these groups are a cause or a
consequence of inflammation.

While there is no firm definition of ‘adulthood’ in laboratory mice, in the literature mice from 68 weeks of age have been classified as adult [56,67,111]. Our data shows that there are
significant differences in the microbiome even within tight age ranges. I identified differences in
colitis severity between age mice of 4-5 weeks of age versus those of 6-7 weeks of age both WT
and Tnf-/- mice and I found unique features in the microbiomes of both age groups. In both
genotypes, 4-5-week-old mice had less severe colitis than 6-7-week-old mice. Six-7-week-old
mice of both genotypes had higher relative abundance of Clostridiales-related microbes.
Decreased Clostridiales in mice has been associated with more severe acute colitis, as well as
decreased expression of butyrate synthesis genes [216]. Butyrate is a short-chain fatty acid that is
known to play a role in maintaining colonic epithelial cells and promoting a healthy gut
environment in both humans and mice [91,157]. Six-7-week old WT mice had higher relative
abundances of Firmicutes and Butyrivibrio. A specific Butyrivibrio strain has been shown to
ameliorate DSS colitis in mice, as well as increase intestinal butyrate production [182]. Future
studies could explore whether Butyrivibrio would have the same positive effect in TNBS colitis,
and whether abundance increases with age. Lactobacillus species are generally associated with
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protection from colitis [191,203]. Not surprisingly, I found that 4-5-week old WT mice had
greater proportions of Lactobacillus pre-colitis and post-colitis. I also observed that
Bacteroidetes, Bacteroidales, and Unclassified Bacteroidales S24-7 did not remain a significant
feature of the microbiome of 4-5-week old WT mice post-colitis. Lower levels of Bacteroidetes
have been associated with active IBD in humans [225]
The microbiomes of age matched WT and Tnf-/- mice shared select few distinguishing taxa,
which supports our hypothesis that TNF expression has a profound impact on microbiome
composition and suggests a role for TNF expression in the gut microbiome composition during
development. In our study, I evaluated mice of two very close age groups and showed that there
were significant differences in the microbiome between the 2 groups. This highlights how mouse
age contributes to the microbiome, and microbiome studies should use tightly age-matched
animals to prevent having age as a confounder. It also supports a recent review that presents
general equivalencies between mouse and human age ranges. Briefly, 4-5-week-old mice are
equivalent to humans at the weaning stage, approximately 6 months of age. 6-7 week old mice
are equivalent to humans at the beginning of adolescence, or approximately 12 years of age [56].
Our CCA also revealed that mouse age was strongly correlated with colitis scores. This suggests
that mouse age may impact colitis severity, and should therefore be reported in colitis studies and
considered when comparing colitis studies in the literature.
Although I did find similar trends across WT and Tnf-/-mice when I analyzed microbiota
composition and colitis development among different age groups, I also identified unique
differentiating microbial taxa that were associated with age in each genotype. Taken together,
these results suggest that TNF expression has an impact on the gut microbiome of mice as they
transition from weaning to pubescent to adult, and likely influencing immune system
development. We have previously reported a role for TNF in modulating the gut microbiome and
driving colitis using only female mice [108]. In addition to providing evidence for sex and age
differences in WT mice, the results of this expanded study confirmed our previous results, and
further suggest a role for TNF in differentially shaping the gut microbiota in a sex and age
dependent manner. This underscores the critical importance of considering these variables when
designing experiments, especially in studies with a microbiome component.
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We described here sex-dependent microbial groups associated with WT and Tnf-/- mice of the
B6.129S strain. I also described differences in the mouse gut microbiome associated with age.
Our study provides evidence that suggests a critical impact of sex and age on the microbiome
that should be considered when designing experiments that will include microbiome data. Our
data also suggests that these sex and age effects on the microbiota may influence the response of
the animal to acute colitis. More studies are needed to unravel the potential contributions of the
microbes I identified to the development of colitis. Taken together, this data shows that
consideration of experimental/environmental factors and their potential impact on the gut
microbiota is imperative when analyzing data from animal studies.
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Figure 2.1 Significant differences in beta-diversity associated with experiment. Principal
Coordinate Analysis (PCoA) of the Bray Curtis metric shows significant separation on PC1
associated with experiment. PERMANOVA p<0.01. PC1 explains 23.17% of the total variation.
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Figure 2.2 Female WT mice and Tnf-/- mice of both sexes have less colitis than male WT mice.
H&E of representative photomicrographs of the colons of A. male TNBS treated WT (n=4) and
B. female TNBS treated WT (n=10); C. male TNBS treated Tnf-/- (n=3) and D. female TNBS
treated Tnf-/- mice (n=10). E. Histopathological semi-quantitative scores are presented as the
mean score ± SEM. Scale bar is 100µm. Significant differences found using Kruskal-Wallis for
overall significance, followed by pairwise Mann-Whitney tests. Asterisks indicate significance.
p<0.05. Mice shown are mixed ages (4-8 weeks).
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Figure 2.3 Sex contributes to differences in the fecal microbiome pre-colitis.
A. Significant differences in species richness by sex (combined genotypes) in untreated mice
(pre-colitis) were found using nonparametric t-test with 999 Monte Carlo permutations (p<0.05)
red line indicates female mice (n=39), blue line indicates male mice (n=10). B. Sex associated
differences in WT beta diversity pre-colitis were found using Adonis and PERMANOVA (p<
0.05). PERMDISP indicated that dispersion does not contribute to significance. C. Sex
associated differences in Tnf--/- beta diversity pre-colitis were found using Adonis and
PERMANOVA (p< 0.05). PERMDISP indicated that dispersion does not contribute to
significance. D. Histogram of the results of Linear Discriminant Analysis Effect Size (LEfSe) of
sex differences in WT TNBS (female n=20, male n=6) mice pre-colitis and E. Tnf--/- TNBS
(female n=19, male n=4) mice pre-colitis. Mice in these studies are not separated by age (range
of 4-8 weeks). Longer bars indicate stronger impact of a certain taxa to the difference between
the two groups. Bars point in opposite directions for visual clarity only and do not indicate
opposite trends in abundance; p-values <0.05 considered significant.
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Figure 2.4 Taxa that contribute significantly to the differences between male and female mice of
both genotypes. A. LEfSe histogram of taxa that are significantly more abundant in male and
female Tnf--/- mice, post-colitis (female n=19 male n=4) p-value <0.05 considered significant B.
LEfSe histogram of identified significantly more abundant taxa in male and female WT mice
post-colitis (female n=20 male n=6) and their effect sizes; p -values <0.05 considered significant.
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Figure 2.5 Age contributes to differences in colitis severity and the gut microbiome composition
of WT and Tnf-/- mice A. Representative H&E stained photomicrographs of the colons of WT
TNBS and Tnf--/- TNBS treated mice (WT 4-5-week-old mice, n=5; WT 6-7-week-old mice, n=5,
Tnf--/- 4-5-week-old mice, n= 5; Tnf--/- 6-7-week-old mice, n=8). Scale bar is 100µm. B.
Histopathological semi-quantitative WT and Tnf--/- colitis scores of both age groups are presented
as mean ± SEM. Significant differences found using overall ANOVA followed by pairwise
Mann-Whitney test. * indicates significance p<0.05, ** indicate significance p< 0.01.
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Figure 2.6 Taxa that contribute significantly to differences in the fecal microbiome of WT mice
associated with age. A. Histogram of the results of LEfSe associated with age in WT mice precolitis (4-week-old mice, n=12; 6-7-week-old mice, n=10); all taxa shown are significant at
p<0.05. B. Cladogram representing the identified pre-colitis WT age-related differentiating taxa
in a taxonomic tree that emphasizes their phylogenetic relationship. Shaded areas distinguish
branches on the tree that correspond to experimental groups. C. Histogram of the results of
LEfSe of associated with age in WT TNBS treated mice post-colitis and their respective effect
sizes; p-values < 0.05 considered significant. D. Cladogram representing the identified postcolitis WT TNBS treated -age related differentiating taxa in a taxonomic tree.
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Figure 2.7 Taxa that contribute significantly to differences in the fecal microbiome of Tnf--/-mice
associated with age. A. Histogram of the results of LEfSe of associated with age in Tnf--/- TNBS
mice pre-colitis and their respective effect sizes (4-5-week-old mice, n=10; 6-7-week-old mice,
n= 13); p values < 0.05 considered significant. B. Cladogram representing pre-colitis Tnf--/TNBS age related differentiating taxa in a taxonomic tree. C. Histogram of differentiating taxa
associated with age in Tnf--/- TNBS mice post-colitis and their respective effect sizes; p-values <
0.05 considered significant.
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Figure 2.8 Age, sex, and TNF status are significant factors influencing the fecal microbiome and
colitis severity. CCA model was performed with day 10 fecal microbiome relative abundances as
the species matrix and the environmental variables of Age, Sex, colitis (score), and Genotype
included in the environmental matrix. Variable biplot arrows indicate direction of environmental
gradient. Relative length of arrows corresponds to the importance of the respective variables in
our model. Angle between arrows corresponds to the relationship of the environmental variables
to one another. Age and Colitis score are closely associated with each other. Overall p=0.003.
Axes 1, 2, and 3 explain 51.0%, 23.5%, and 19.6% of the total constrained variation.
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CHAPTER 3.
SPATIAL COMPOSITION OF THE GUT MICROBIOME
ASSOCIATED WITH SEX, TNF, AND CHRONIC TNBS COLITIS

3.1

Introduction

Crohn’s Disease (CD) is a subtype of Inflammatory Bowel Disease (IBD) that can affect any
region of the GI tract. Although the exact cause of CD is unknown, a dysbiotic configuration of
the gut microbiome has been associated with the disease. Crohn’s is a chronic disease, thus
studying alterations in the microbiome in a mouse model of chronic colitis is expected to yield
results that are more comparable to those that occur in human disease. As previously mentioned,
the impact of tumor necrosis factor (TNF), or its blockade by current anti-TNF drugs, on the gut
microbiome during human IBD is not known. Additionally, there is no consensus as to the
degree that sex impacts the microbiome. Fecal samples are widely used to survey the
microbiome in mouse studies of IBD. However, human studies often use biopsy samples to
survey the mucosal surfaces involved in active inflammation. A major difference between the GI
tract of mice and humans is the role of the cecum. In mice, the cecum is the site of fermentation
and nutrient absorption [84]. Therefore, the microbial community of the cecum is likely home to
many microbes that participate in fermentation and produce beneficial short-chain fatty acids
(SCFAs). Short-chain fatty acids are often the focus of human studies, as they are known to
regulate inflammation. In humans, SCFAs are produced in the colon, and SCFA-producing
microbes found in the colon have been linked to anti-inflammatory activity [117,246]. It could be
that

alterations

in

beneficial

microbes

are

best

observed

in

the

cecum.

2,4,6

trinitrobenzenesulfonic acid (TNBS) colitis is induced by intra-rectal introduction of the
chemical and although the mice are suspended upside down to allow the chemical to traverse as
much of the colon as possible, little if any reaches the cecum. Profiling of the cecal microbiome
is needed to determine whether there are colitis associated differences in the cecal microbial
populations that are not seen in the feces.

I have shown that age, sex, and TNF expression impact the gut microbiome in acute TNBS
colitis. In this chapter, I sought to accomplish two objectives. The first objective was to
determine the impact of sex and TNF on the fecal microbiome in chronic TNBS colitis. I
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hypothesized that Tnf-/- mice would have significantly less colitis than WT mice, and that sex and
TNF would impact the fecal microbiome. The second objective was to compare the microbiomes
of the feces, cecum, and colonic mucus in WT mice with chronic TNBS colitis and determine
which community is most closely correlated with colitis. I hypothesized that the fecal
microbiome would most closely correlate with TNBS colitis. To test these hypotheses, I
collected fecal samples for Illumina MiSeq sequencing before and after chronic TNBS colitis
induction in WT and Tnf-/- mice, as well as cecal content at necropsy and mucus scraped from the
distal colon at necropsy to determine the composition and microbial diversity of the cecum and
colonic mucus.

3.2
3.2.1

Methods
Mice

Male and female WT C57BL/6J (WT) mice were obtained from The Jackson Laboratory (Bar
Harbor, ME) and male and female C57BL/6J mice with a homozygous (-/-) deletion of the Tnf
gene (Tnf-/-) were obtained from the National Cancer Institute (Frederick, MD). Both genotypes
of mice were subsequently bred and housed at Purdue University for at least two generations
before mice were selected for these experiments. Mice were housed in specific pathogen free
conditions and maintained on 12hr light/dark cycles with free access to food and water. Mice
were fed with 2018s mouse chow (Envigo). Mice were caged separately by sex, genotype (Tnf-/vs WT) and treatment (TNBS vs SHAM). Mice were 8-9 weeks old at the start of each
experiment. Mice are described in the figures and text by their assigned treatment group (TNBS
or SHAM), however all mice at day 0 are ‘untreated’ and so mice from the TNBS groups at day
0 are referred to as ‘pre-colitis’.
3.2.2

Chronic TNBS Colitis

Power calculation based on the results from B6.129S mice in Chapter 2 determined that at least
three mice per treatment group were needed. The experiments were performed three times with
at least three mice in each treatment group. Colitis was induced as previously described in
Chapter 2 with the following modifications; the injection was repeated four times, one injection
each week, for a total of five injections. Mice were fasted from food for 24 hours before each
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injection and were weighed twice per week. Three days after the fifth IR injection necropsy was
performed and tissues were harvested. Mice were euthanized by an overdose of CO2 followed by
cervical dislocation. Fecal samples for microbial community analysis were collected on days 0,
10, and necropsy and immediately frozen and stored at -80°C until analyzed. The cecum was
resected, weighted, and its contents collected for microbiome sequencing. A section of the distal
colon was collected in formalin for histological analysis. Mucus was collected from the
remaining colon tissue by gentle scraping, immediately frozen, and stored at -80°C.
3.2.3

Histological Assessment of Colitis

Colon tissue was sampled and colitis was assessed as described in Chapter 2.
3.2.4

DNA Extraction and Sequencing

Total DNA was extracted from each fecal, cecal, and mucus samples using the FastDNA Spin kit
for soil (MP Biomedicals), with bead beating, per the manufacturer’s instructions. DNA quality
and quantity were assessed as described in Chapter 2. Primers that amplify the V3-V4 region of
the 16S rRNA gene were used on fecal DNA from day 0 and day 38 (necropsy). The resulting
amplicons were sequenced using MiSeq Illumina 2x 250 paired end sequencing as described in
Chapter 2.
3.2.5

Sequence Processing

Panda software [154] was used to merge high-quality reads after the removal of primer tags and
low quality sequence reads. Sequences were analyzed using the QIIME pipeline version 1.9.1
[32]. The “pick open reference OTU” option with default variables and the Greengenes data set
(version 13_8) were used to assign taxonomy to the representative OTU sequences. All
subsequent comparisons were performed using equivalent numbers of sequence reads (based on
the lowest number of sequences obtained from a single sample) per sample that was chosen by
rarefaction, unless otherwise noted in the text. Good’s coverage provided an estimate of
sequence coverage of the communities used in these analyses. Rarefied analyses of alpha
diversity indices (Chao1, observed OTUs, Shannon) were calculated to compare microbiota
community diversity within each sample. Beta diversity comparisons among communities were
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made using the phylogenetic distances unweighted and weighted UniFrac [145] as well as nonphylogenetic distance analysis using Bray Curtis distances.
3.2.6

Statistical Analysis

All basic statistics were performed using GraphPad Prism version 7.00 for Windows (GraphPad
Software, La Jolla California USA). Histological scores were statistically analyzed as described
in Chapter 2. All data in bar graphs or dot plot formats are expressed as mean ± S.E.M.
Statistical significance is p <0.05. Microbial diversity was assessed with alpha and beta diversity
measures. Alpha diversity is the microbial diversity within each sample, and it can be measured
by a variety of metrics such as observed species, (a richness metric, measures the number of
different taxa present in a sample), Simpson’s evenness (measures how equally the present
species in a sample are represented), or a combined metric like Shannon diversity that considers
both richness and evenness. Shannon diversity was used to report alpha diversity in this study.
Significant differences in alpha diversity were computed with a non-parametric t-test with 999
permutations. Beta diversity is the microbial diversity between samples. It is computed using
distance matrices (such as Bray-Curtis, unweighted UniFrac, and weighted UniFrac) that depict
how dissimilar two microbial communities are from one another. Significant differences in beta
diversity were determined as described in Chapter 2.

The type of information most commonly reported in microbiome data is the relative abundance
of certain taxa. However, relative abundances have an inherent sum constraint, as the relative
abundance within a sample/individual always sum to 1. The relative proportions between
samples may or may not reflect true population dynamics and can lead to false conclusions about
the role of certain taxa in a system. It also means that the observations themselves are not truly
independent. To mitigate these shortcomings, Analysis of Composition of Microbiomes
(ANCOM) utilizes compositional log-ratios to identify statistically significant taxa [150].
Moreover, compositional data generally contains lots of zero values, which is another statistical
complication. While ANCOM is not a perfect statistical solution, it has been shown to have a
lower false discovery rate (FDR) and higher statistical power than simple t-test methods. I
employed a combined approach for the microbiome analyses in this study to report biologically
relevant results with confidence. Linear Discriminant Analysis Effect Size (LEfSe) [218]
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analysis identifies taxa that contribute significantly to the differences in the microbiomes
between experimental groups of interest, and estimates effect size. Alpha was set to 0.05 and
‘all-against-all’ class comparison method was used. For more robust taxonomic comparisons
ANCOM was applied. Although both LEfSe and ANCOM identify differentially abundant taxa,
LEfSe ranks the taxa according to their effect sizes, whereas ANCOM only reports statistical
significance. Using both of these methods can tell us not only which taxa are significantly
different between experimental conditions, but also the magnitude of the difference attributed to
each taxon. ANCOM has been shown to have a lower false discovery rate (FDR) and higher
statistical power than simple t-test methods and Zero-Inflated Gaussian methods [150].

Simple Pearson and Spearman correlation methods have often been used to predict correlations
between taxa in a dataset and other environmental variables, but these do not account for the
unique features of microbiome data that I discussed above. Simple correlation methods can lead
to spurious correlations and conclusions when used on compositional data. I use the newly
introduced SParse InversECovariance Estimation for Ecological ASsociation Inference (SPIECEASI) method [124] to identify co-occurrence relationships in my data. This method accounts
for the compositionality of my data to allow for the statistically robust analysis of taxon
interaction networks. SPIEC-EASI generates co-occurrence models that can be used to predict
taxon-taxon interactions in microbial community data. These proposed interactions provide an
excellent starting point for identifying keystone species and species that warrant further
functional studies. This method accounts for the compositionality of data to allow for a
statistically robust analysis of taxon interaction networks [63]. Analyses were performed in R
[233]

(packages:vegan31,MASS32,

“https://github.com/zdk123/SpiecEasi”),

vegan3d,
phyloseq;

spiec-easi

(available

http://www.R-project.org/).

at

Network

visualization and analysis was conducted in Cytoscape (version 3.6) [39,219].

I also performed Canonical Correspondence Analysis (CCA) [26] to determine speciesenvironment relationships and the interactions between sets of variables in my data. This allowed
me to understand how the host variables, (such as sample location, mouse strain, sex, age, TNF
status, and colitis response) interact and influence the taxa relative abundances. CCA was
implemented with the R package “vegan”. CCA model significance was tested with ANOVA
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and step-wise analysis. Canonical correspondence analysis (CCA) was used to determine
associations between environmental variables (sex, GI site, age, colitis severity, and treatment
were tested; final model included treatment and GI site), colitis scores, and taxon relative
abundance among communities.

3.3
3.3.1

Results – Chronic TNBS colitis in WT mice
Sex impacts chronic TNBS colitis in WT mice

Histological evaluation of colon tissue stained with hematoxylin and eosin revealed that TNBS
treated female WT mice had more severe colitis than male TNBS treated WT mice (Figure 3.1 B,
D). Additionally, WT TNBS treated female mice had significantly lower survival over the course
of the experiment, and there was no difference in survival between male and female SHAM mice
(Figure 3.1C). TNBS treated mice developed more severe colitis than control mice (Figure 3.1
A), but there were no significant differences in body weight change between TNBS and SHAM
mice (not shown). There were no sex differences in the fecal microbiomes of WT mice precolitis (not shown).
3.3.2

TNBS treatment results in significant alterations in the microbiomes the feces, cecum,
and the mucus of WT mice

3.3.2.1 TNBS associated differences in microbial diversity.
Analysis of 7,900 rarefied sequences per sample (Good’s coverage approximately 98%) of
TNBS and SHAM treated mice revealed no treatment associated differences in alpha diversity
(Shannon diversity metric) in the fecal, cecal, or mucus microbiomes. The feces of TNBS treated
mice had significantly less Shannon diversity than the cecum and colon mucus (Figure 3.2A).
Principal Coordinate Analysis (PCoA) of the Bray Curtis distance shows that TNBS treatment
resulted in significant differences in beta diversity in the feces (PERMANOVA p<0.05),
separating along PC1 and explaining about 30% of the total variation in the data (Figure 3.2B).
PERMDISP indicated that dispersion did not contribute to significance. TNBS treatment also
resulted in significant differences in beta-diversity in the mucus (PERMANOVA p<0.05), also
separating along PC1 and explaining about 76% of the total variation in the data. (Figure 3.2 C).
PERMDISP indicated that dispersion did not contribute to significance.

No significant
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differences in beta diversity were associated with TNBS treatment in the cecum. Similar trends
were observed in all three beta diversity metrics (Bray Curtis, weighted UniFrac, and unweighted
UniFrac) tested. Principal coordinate analysis of the unweighted UniFrac distance shows that the
post-colitis samples cluster by spatial distribution along the GI tract regardless of treatment
(Figure 3.3). The samples separate along PC1, which explains approximately 20% of the total
variation in beta-diversity. PERMDISP indicated that dispersion did not contribute to
significance.

3.3.2.2 TNBS associated differences in community composition
Significantly different phyla between TNBS and SHAM treated mice across the feces, cecum,
and mucus were determined using Kruskal Wallis with follow-up pairwise tests (p-values
corrected for multiple comparisons with Dunn’s test). In the mucus samples, TNBS treated mice
had significantly lower Bacteroidetes and significantly higher Firmicutes than SHAM treated
mice (Figure 3.4A). Since all samples were dominated by four phyla, the low abundance phyla
are plotted separately (Figure 3.4B). TNBS treatment was associated with a significantly lower
relative abundance of Deferribacteres in the cecum and the mucus. Chloroflexi and
Cyanobacteria were significantly lower in TNBS treated mucus samples compared to SHAM,
and significantly lower relative abundances of TM7 were found in TNBS treated feces and
mucus compared to SHAM. ANCOM with false discovery rate (FDR) multiple comparisons
correction showed significant differences at the genus level (Figure 3.5). Microbial cooccurrence modeling with SPIEC-EASI identified a microbial interaction network in the WT
mucus environment (treatments combined). Desulfovibrio and Sutterella were shown to have
several interactions with members of the Firmicutes phylum, and Mucispirillum schaedleri
interactions with both Firmicutes and Bacteroidetes were observed (Figure 3.6).
3.3.3

The mucus microbiome is more closely associated with colitis than is that of the feces or
cecum

To assess which GI location was reflective of colitis, I used Canonical Correspondence Analysis
(CCA) on the taxa relative abundances at necropsy to examine the species-environment
relationships. The angle between the variable bi-plot arrows is indicative of the relationship of
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the variables to one another. TNBS treatment is associated with colitis score, and the mucus is
more closely associated with colitis score than the feces. The cecum was confounded with the
feces and was excluded from the final model. The fecal and cecal sample types were closely
associated with CCA1, which explains 52.6% of the constrained variation. TNBS treatment and
colitis score was associated with CCA2 and CCA3, which explains 23.8% and 15.2% of the
constrained variation, respectively (Figure 3.7).

3.4
3.4.1

Results- Chronic TNBS colitis in Tnf -/- mice compared to WT mice
The fecal microbiomes of WT and Tnf -/- mice pre and post colitis are distinct

3.4.1.1 Significant differences in microbial diversity
Analysis of 2,121 sequences per sample (Good’s coverage approximately 96%) revealed that the
fecal microbiomes of Tnf-/- mice were significantly different from WT mice at day 0. I observed
that WT mice exhibited significantly lower alpha diversity as measured by Shannon index
(Figure 3.8A). Principal coordinate analysis of the Bray Curtis metric also revealed clear
separation of the fecal microbiomes by TNF expression along PC1, which explains
approximately 62% of the total variation in beta diversity pre-colitis (PERMANOVA p=0.001).
PERMDISP indicated that dispersion did not contribute to significance (Figure 3.8B). Postcolitis, analysis of the fecal microbiome revealed significant differences in alpha and betadiversity between WT and Tnf-/- mice. WT mice had significantly lower alpha diversity than Tnf/-

mice as measured by the Shannon index (Figure 3.8C). Principal coordinate analysis of the

Bray-Curtis distance shows that the fecal microbiomes of mice separate by genotype along PC1,
which explains approximately 35.4% of the total community variation (PERMANOVA
p=0.001). Significant PERMDISP (p=0.001) indicates that dispersion may have contributed to
significance (Figure 3.8D).

3.4.1.2 Significant differences in community composition
Linear discriminant analysis effect size (LEfSe) identified taxa that were contributing to the
differences between the fecal microbiomes of WT and Tnf-/- mice (Figure 3.9) pre-colitis.
Bacteroidales S24-7, Lactobacillus, Turicibacter, and Bifidobacterium were found to have
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significantly higher relative abundances in WT mice. Bacteroides and Parabacteroides were
found to have significantly higher relative abundances in Tnf-/- mice.
3.4.2

Tnf -/- mice tend to have less severe chronic TNBS colitis than WT mice

Analysis of the colitis scores of WT and Tnf-/- mice were inconclusive. Tnf -/- mice tended to have
less severe colitis than WT mice (p=0.0512) (Figure 3.10).
3.4.3

The cecal microbiomes of WT and Tnf -/- mice with colitis are distinct

3.4.3.1 Significant differences in microbial diversity
Analysis of 7,000 sequences per sample revealed that Tnf

-/-

mice had higher species richness

(Figure 3.11 A) and Shannon diversity (Figure 3.11C) than WT mice after TNBS treatment.
There were also significant differences in beta diversity (Figure 3.11B). Principal coordinate
analysis of the Weighted UniFrac metric revealed that the cecal microbiomes of mice separate by
TNF expression (PERMANOVA p=0.001). Separation was along PC1, which explains 64% of
the community variation. PERMDISP indicated that dispersion did not contribute to significance.
3.4.3.2 Significant differences in community composition
Linear Discriminant Analysis Effect Size (LEfSe) identified taxa that contributed significantly to
the differences in the cecal microbiomes of WT and Tnf -/- mice (Figure 3.12) (p<0.05). WT mice
had significantly higher relative abundances of Firmicutes, especially Clostridia, and Tnf -/- mice
had significantly higher relative abundances of Bacteroidetes, especially Bacteroidales S24-7.
3.4.4

Sex impacts the cecal microbiome of Tnf -/- mice with colitis

Linear Discriminant Analysis Effect Size (LEfSe) identified taxa that contributed significantly to
the differences between the cecal microbiomes of male and female Tnf
Taxa with the highest effect sizes in male Tnf

-/-

mice (Figure 3.13).

mice included unclassified Clostridiales and

Coriobacteria. Taxa with the highest effect sizes in female Tnf
belonging to the candidate phylum TM7.

-/-

-/-

mice included several groups
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3.5

Discussion

The objectives of this study were to identify microbes that were significantly altered during
chronic TNBS colitis in WT and Tnf

-/-

mice, and to compare the microbiomes of the feces,

cecum, and mucus in WT mice after TNBS colitis. I have shown that although the fecal stream,
mucus layer, and cecum of mice are parts of the same (relatively small, in mice) system, the
bacterial communities at each site are quite different. All three sites share the same major phyla,
Firmicutes, Bacteroidetes, Actinobacteria, and Proteobacteria. However, the relative proportions
of Firmicutes and Bacteroidetes differ. The cecum was dominated by Firmicutes post-colitis and
had low relative abundances of Bacteroidetes and Proteobacteria, which has been reported before
in other C57BL/6J laboratory mice [205,231]. Interestingly, wild mice have been found to have
near-equal proportions of Firmicutes, Bacteroidetes, and Proteobacteria, which was associated
with anti-inflammatory effects and resistance to infections [205]. This highlights the importance
of understanding the relationship between host genetics and the microbiome.

In this study, I hypothesized that the fecal samples would be most informative during TNBS
colitis, mainly due to the method of TNBS colitis induction. However, the mucus samples
revealed the presence of colitis-associated microbes that have been associated with human IBD
[86,243]. Mucus from TNBS treated mice had significantly lower relative abundance of
Bacteroidetes than SHAM treated mice. Decreased abundances of members of Bacteroidetes
have been reported in IBD patients with active inflammation [265]. There were significantly
higher relative abundances of Desulfovibrio; a genus of sulfate reducing bacteria (SRB), in the
mucus of TNBS treated animals compared to SHAM animals. This finding is consistent with
other reports that SRB are increased in the colon of mice with TNBS colitis , associated with a
more penetrable mucus phenotype, and are increased in the mucosa of patients with IBD
[86,106,243]. Moreover, it has been shown that SRB accentuates the damage caused by TNBS
and is associated with increased cytotoxic hydrogen sulfide production and a Th-17 immune
response [66,202]. I also found significantly higher relative abundance of Dehalobacterium in
TNBS mucus samples compared to SHAM. While the role of Dehalobacterium in IBD is
unknown, it has been positively associated with tumorigenesis in a mouse model of colorectal
cancer [165]. There were also significantly higher relative abundances of Ruminococcus and
Staphylococcus in TNBS mucus samples compared to TNBS fecal samples. Some members of
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Ruminococcus are known to degrade mucins in the mucus layer, which provides an energy
source for other bacteria [157]. Damaged and inflamed mucosa could provide an environment for
bacteria that are not normally associated it, thereby continuing to provide inflammatory stimulus.
Co-occurrence modeling identified Mucispirillum schaedleri in the mucus samples and revealed
interactions with members of both the Bacteroidetes and Firmicutes phyla. M. schaedleri is
associated with intestinal mucus degradation in laboratory mice. It is not clear whether it plays a
specific role in acute colitis, but others have proposed that its activity may provide other gut
microbes with alternative energy sources in the form of degraded mucins [16].

The results of the CCA also suggest that the mucus microbiome is reflective of TNBS colitis
activity, perhaps providing more useful information than fecal samples alone. Fecal samples are
widely used in microbiome studies on animal models to capture a glimpse of the microbial
community under different conditions [49]. Despite some debate on their degree of relevance to
human IBD (CD does not always occur in the colon), mouse fecal samples are abundant, easy to
collect, and remain a relatively cost-effective way to survey the microbiome in models of IBD.
However, human studies often examine patient biopsies, actual tissue from the diseased areas
(often at time of diagnosis), to identify taxa associated with active inflammation. Studies have
shown that the microbiome profile generated from feces (considered to be representative of the
lumen) compared to biopsies are not identical [132,251]. Although biopsies may cause
discomfort for patients, in human studies the information gained from communities directly
associated with active sites of inflammation is invaluable. Therefore, the information gained
from sampling directly at the site of inflammation in mice could provide a more accurate
reflection of microbial activity during inflammation.
I also hypothesized that Tnf-/- mice would have less severe colitis than WT mice. The histology
data was inconclusive, but Tnf-/- mice tended to have less severe colitis than WT mice. Post-hoc
power calculation based on the results of the chronic study indicated that 10 mice per group (for
a grand total of 80 mice per experiment instead of the 44 used here) would be needed to achieve
statistical power of 80% when using C57BL/6J mice. The rationale for my hypothesis was based
on my previous acute study, in which the Tnf-/- mice had significantly lower colitis scores.
However, the chronic colitis results showed that the colitis scores tended to be similar between
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WT and Tnf-/- mice, with the Tnf-/- mice having slightly lower scores (WT average score = 5.4,
Tnf-/ average score = 4.3)-. A major difference between the acute and chronic colitis studies was
the strain of mouse used. In the acute studies, I used B6.129S mice. However, these mice did not
survive the multiple injections required for the chronic studies and C57BL/6J mice were used for
the chronic experiments. This is likely due to differences in susceptibility to colitis between the
B6.129S mice and C57BL/6J mice [9,85]. This highlights the importance of mouse strain in IBD
animal models. The impact of mouse strain on the microbiome will be discussed further in a later
chapter. Despite the inconclusive colitis data, there were significant differences in the fecal
microbiomes of WT and Tnf-/- mice before and after chronic TNBS colitis. Lactobacillus,
Turicibacter, and Bifidobacterium were identified by LEfSe as being significantly more
abundant in WT mice before TNBS colitis. This data suggests that these genera may play a
protective role in C57BL/6J mice challenged with TNBS [57,248]. Lactobacillus and
Bifidobacterium have been shown in several studies to be associated with health in the gut
microbiome [137,200,259]. Additionally, Lactobacillus species from healthy C57BL/6J mice
have been shown to inhibit TNF production, while other Lactobacillus species from IL-10
knockout mice with colitis did not inhibit TNF [191]. Oral administration of certain strains of
Bifidobacterium has been shown to impede the development of DSS colitis in mice [72,225].
While the role of Turicibacter in IBD is unknown, we have repeatedly identified it as a major
genus in the mouse fecal microbiome [108,122].

I also sought to understand how sex impacts the microbiome before and after chronic colitis.
Although WT female mice did have more severe colitis than WT male mice, there were no sex
associated differences in the microbiome of WT mice before or after TNBS colitis. This
contrasting result may be due to the different strain of mouse used in the chronic studies. This
highlights the importance of considering the impact of host variables on the microbiome,
especially any sex differences, in the context of colitis. There has been conflicting evidence for
sex differences in the microbiomes of mice and humans. However, several studies have found
sex-associated differences in immune responses [29,62,119]. In humans, females have been
shown to have stronger responses to infection and stronger antibody-production [126,147]
whereas males have been shown to have stronger Th1 driven immune responses [62,80]. Similar
findings have also been reported in mice

[112,162,163,173]. Data from my acute studies
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identified sex as an important factor contributing to variation in the fecal microbiome [122]. A
recent study found microbiome-independent sex differences in the B cell development, Th cell
differentiation, and antigen-presentation pathways in systems of germ free C57BL/6J mice [70].
Additionally, transfer of female and male microbiomes to germ-free (GF) mice of the opposite
sex resulted in the identification of several sex-associated differences in the immune system. The
authors proposed that microbiota-independent differences in the immune system of male and
female mice select for sex-specific microbiome configurations. These configurations could then
drive additional sex-differences in immunity [70]. More studies will be needed to elucidate the
exact mechanisms that contribute to this phenomenon, and how it is related to the microbiome.
I also looked at how TNF impacts the gut microbiome during chronic TNBS colitis. Tnf-/- mice
had a significantly different fecal and cecal microbiome than WT mice. This is supported by
previous work in our lab that established TNF impacts the fecal microbiome as well [108,122].
TNF has systemic effects on the inflammatory process. Evidence for an impact of TNF on cecal
microbiome points to the potential of TNF to interact with microbes that produce short-chain
fatty acids (SCFAs). Short-chain fatty acids have been shown to inhibit TNF induced
inflammatory signaling [103,246]. More studies are needed to investigate the functional
consequences of TNF ablation in the cecal microbiome. Tnf-/- mice also showed sex associated
differences in the microbiome before chronic TNBS colitis. This is in contrast to the absence of
sex associated differences in microbiome diversity or composition of WT mice. More studies are
needed to explain the relationship between TNF expression and sex-specific microbiome
configurations.
Technical difficulties related to sequencing bacterial DNA from the mucus of Tnf-/- mice limited
my ability to examine the potential impact of TNF on the mucus microbiome, so additional
studies are needed to determine whether a similar impact occurs in the mucus. The mucus of Tnf/-

mice was thinner and harder to collect than the mucus of WT mice. Additionally, PCR

amplification of the V3-V4 region of the 16S rRNA gene Tnf-/- mucus did not yield sufficient
quantities of product to sequence in a number of samples. Future studies should consider ways to
increase the amount of mucus collected and/or optimize extraction/PCR conditions for isolating
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bacterial DNA from mucus. A higher quantity of mucus may be more easily obtained from larger
animals, like rats.

In summary, this chapter presents the results of my chronic TNBS colitis study. My hypotheses
were that Tnf-/- mice would have less severe colitis than WT mice; Sex differences in the
microbiome would impact colitis severity; and the impact of TNBS colitis on the microbiome is
most readily seen in fecal samples. Tnf-/- mice and WT mice experienced a similar level of colitis,
with a trend of Tnf-/- mice having slightly less severe colitis. However, WT and Tnf-/- mice had
significantly different microbiomes. Additionally, there were no sex differences in the
microbiomes of WT mice, even though the female WT mice had more severe colitis than male
mice. My data shows that the feces, cecum, and mucus sites each have their own unique
microbiome profile More extensive sampling, (including baseline mucus samples, sampling from
inflamed and normal areas in the same mouse, sampling from different regions of the GI tract,
and increased sample size) in future TNBS colitis studies would likely result in the identification
of microbes with direct impacts on TNBS-induced inflammation. Lastly, further studies into the
interaction between sulfate-reducing bacteria, hydrogen sulfide production and the intestinal
mucosa would provide an understanding of how specific mucus-associated bacteria may
participate in gut barrier disruption and drive inflammation.
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CHAPTER 4.
THE GUT MICROBIOME ACROSS THREE
COMMONLY USED STRAINS OF LABORATORY MICE

4.1

Introduction

Recent interest in the microbiome has led to a rapid increase in the number of studies
investigating the role of the microbiome in a particular disease. However, microbiome studies
have inherent challenges that researchers must consider. Humans have a very high level of interindividual microbiome variation that makes it hard to discern distinct disease associated trends
[88,120] The popularity of mouse models for microbiome research is partially due to the
availability of inbred mice with similar genetic backgrounds. Mouse models have proven to be
valuable tools for studying a variety of diseases. They have been particularly useful for
unraveling the specific mechanisms behind microbe-host crosstalk as well as the impact of the
gut microbiome on the immune system. However, recent studies have begun to highlight sources
of variation that may complicate the translation of mouse data back to humans [122,178]. For
example, most colitis studies are conducted in either BALB/c or C57BL/6J mice [9]. However,
using different strains can lead to different results. As previously discussed, C57BL/6J mice are
more resistant to colitis, while BALB/c mice are more susceptible. In the previous chapters, I
induced TNBS colitis in C57BL/6J mice as well as B6.129S mice. B6.129S mice are the product
of a cross between C57BL/6J mice and 129S1/SvImJ (129) mice. Strain 129 mice are more
readily susceptible to colitis, similar to BALB/c mice [85]. There are also physiological
differences that are linked to mouse strain. For example, 129 mice have fewer Paneth cells than
C57BL/6J. It has also been reported that the impact of certain host factors, such as sex, affects
the microbiome in a strain dependent way [127]. Therefore, comparing data from mouse studies
back to the literature without considering the strain of mouse may result in a failure to recognize
trends in microbiome data that are overshadowed by larger host effects. Moreover, other studies
have found that contamination in extraction kit reagent and differences in protocol may also
contribute to microbiome variation [118,127]. In this study, I sought to compare the fecal
microbiomes of three strains of laboratory mice. I hypothesized that the microbiomes of three
commonly used strains of laboratory mice would be significantly different. To investigate this, I
compared the microbiomes of three inbred mouse strains that are commonly used for colitis
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studies, BALB/c, B6.129S, and C57BL/6J to determine if there were significant differences in
diversity and composition of the fecal microbiomes.

4.2
4.2.1

Methods
Mice

Male BALB/c mice were obtained from Harlan and allowed to acclimate at Purdue University
for approximately 2 weeks before fecal samples were taken. Male and female C57BL/6J mice
were originally obtained from Jackson and subsequently bred and housed at Purdue for at least 2
generations before fecal samples were collected, additional male C57BL/6J mice were also
obtained from Jackson, allowed to acclimate at Duke University for approximately 2 weeks
before samples were collected. Male and female B6.129S mice were obtained from Jackson (Bar
Harbor, ME) and subsequently bred and house at Purdue for at least two generations before fecal
samples were collected. An additional subset of male B6.129S mice were obtained from Jackson
and allowed to acclimate at Purdue for 2 weeks before fecal samples were collected. Numbers of
mice are depicted in Table 4.1. Mice were housed in specific pathogen free conditions and
maintained on 12hr light/dark cycles with free access to food and water. Even though the mice
were from various vendors, and the samples were collected at different institutions and time
points, the sample processing and sequencing were completed at the same institution according
to the same protocols and reagents. Therefore, the results here are reported with confidence.
1.2.2 DNA Extraction and Sequencing
Performed as described in Chapter 2.
4.2.2

Data Analysis

Performed as described in Chapter 2.
4.2.3

Statistics

Performed as described in Chapter 2.
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4.3
4.3.1

Results
Mouse strain is associated with significant differences in fecal microbiome diversity

Alpha diversity analysis of 9,000 rarefied reads per sample (Good’s coverage approximately
96%) revealed significant differences in species richness and Shannon diversity among strains.
C57BL/6J mice had significantly lower species richness (as measured by the number of observed
species) than BALB/c and B6.129S mice (Figure 4.1A). All strains of mice had significant
differences in Shannon diversity, which accounts for species richness as well as evenness.
BALB/c mice had the highest Shannon diversity, followed by B6.129S mice, and finally
C57BL/6J mice (Figure 4.1B). Analysis of the Bray Curtis metric and the unweighted UniFrac
metric shows significant differences in beta-diversity among strains. In both metrics, there was
significant separation of the microbiomes by strain. In the Bray Curtis metric, the communities
separated on PC1 and PC2, which explained 31.0% and 19.2% of the total variation, respectively
(Figure 4.2A). The unweighted UniFrac metric revealed separation on PC1 and PC3, which
explained 18.7% and 4.79% of the total variation, respectively (Figure 4.2B).
4.3.2

BALB/c, B6.129S, and C57BL/6J mice have different taxonomic profiles

Taxonomic comparisons of the fecal microbiome of the three mouse strains revealed differences
at the phylum level (Figure 4.3A). The communities of all strains were dominated by the
Bacteroidetes and Firmicutes phyla. BALB/c mice had significantly higher relative abundance of
Proteobacteria than B6.129S and C57BL/6J mice. C57BL/6J mice had a higher relative
abundance of Actinobacteria than B6.129S and BALB/c mice. LEfSe calculated the effect sizes
of significantly different taxa associated with mouse strain. The taxa with the highest effect sizes
were Bacteroidales S24-7 in C57BL/6J mice, unclassified Bacteroidales in BALB/c mice, and
Clostridia in B6.129S mice (Figure 4.3B). ANCOM was used to identify taxa that differ
significantly between strains. A heatmap of the relative abundances was used to visualize the
taxa that were determined to be significant with ANCOM (Figure 4.4). Additional pairwise posttests with p-value adjustments for multiple corrections identified nine significantly different taxa.
Bifidobacterium and Rikenellaceae were the taxa significantly different between C57BL/6J mice
and B6.129S mice.

Bacteroides, Odoribacter, Clostridiaceae, and Oscillospira were all

significantly different between B6.129S and BALB/c mice as well as C57BL/6J mice and
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BALB/c mice. BALB/c mice had significantly higher relative abundances of several taxa
compared to the other two strains, including Bacteroides, Oscillospira, and Odoribacter. They
also had significantly lower relative abundances of Lactobacillus and Lachnospiraceae.
Rikenellaceae AF12 was significantly different between B6.129S and BALB/c mice.
4.3.3

Vendor and Sex associated effects in the fecal microbiome

Both Bray Curtis and unweighted UniFrac revealed distinct clusters based on source (Figure
4.5A, C). There were a few B6.129S mice that clustered with the C57BL/6J mice. Further
analysis revealed that these samples were from mice bought directly from Jackson and sampled
after an acclimation period. Analysis of the fecal microbiomes of male and female mice within
B6.129S and C57BL/6J strains revealed significant differences in beta-diversity (Figure 4.5 B,
D). There were also differences in the taxonomic profiles of male and female mice of each strain
(Figure 4.6A). LEfSe identified taxa that contributed significantly to the differences between
sexes within and across mouse strains. The taxa with the largest effect sizes were the
Actinobacteria phylum and class in C57BL/6J male mice, Rikenellaceae in C57BL/6J female
mice, unclassified Bacteroidales in BALB/c male mice, Bacteroidales S24-7 in B6.129S male
mice, and unclassified Clostridiaceae in B6.129S female mice (Figure 4.7A).

ANCOM

identified significantly different taxa between male and female mice within and across mouse
strains. After pairwise post-test and adjusting for multiple comparisons, four taxa remained
significant. Bifidobacterium had the highest relative abundance in C57BL/6J males. Additionally,
C57BL/6J males and females had significantly higher relative abundances of Bifidobacterium
than B6.129S males and females (Figure 4.7B). Additionally, B6.129S female mice had
significantly higher relative abundance of Lachnospiraceae than male B6.129S mice and
C57BL/6J mice of both sexes. (Figure 4.7C). C57BL/6J mice had significantly higher relative
abundance of Rikenellaceae than B6.129S mice, and C57BL/6J females had significantly higher
relative abundance than males (Figure 4.7D). Bacteroidales S24-7 was significantly less
abundant in B6.129S female mice than male B6.129S mice and C57BL6 mice of both sexes
(Figure 4.7E).
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4.4

Discussion

This study sought to identify differences in the fecal microbiomes of three commonly used
strains of laboratory mice. I compared the microbiomes of healthy male and female B6.129S
mice, male and female C57BL/6J mice, and male BALB/c mice. The three strains analyzed here
had distinct microbiome profiles. BALB/c mice had higher alpha diversity, and higher
abundances of several taxa that were at low abundances in the other two strains.

Mouse vendor and acclimation time also affected the microbiome. B6.129S mice from the acute
experiment and C57BL/6J mice from the chronic experiment were typically purchased from
Jackson labs, and then bred and housed at Purdue for experiments. However, a small subset of
B6.129S male samples came from mice who were allowed to go through a two-week acclimation
period prior to sampling. In our beta diversity analysis, these samples clustered with another
subset of male C57BL/6J mice that were also purchased from Jackson and subsequently sampled
at another institution after a two-week acclimation period. Therefore, the microbiome of mice of
different strains from the same vendor with similar acclimation periods was more similar than
mice of the same strain from different vendors/acclimation periods. This suggests an overall
vendor effect that may outweigh strain-specific differences, which agrees with what others have
reported [59].

I also saw significant sex-associated differences in beta-diversity within the C57BL/6J and
B6.129S mouse strains. In the last chapter, I did not see sex-associated differences in the
microbiomes of C57BL/6J mice. The contrasting result here could be due to the aforementioned
vendor effect. When the male C57BL/6J mice from Jackson were analyzed, significant sexdifferences between the microbiomes of male and female mice were apparent. However, it is
possible that the lack of sex differences in C57BL/6J mice in the chronic study could be due to
confounding by some other variable, or small sample size. Members of Rikenellaceae were
identified as being overrepresented in male mice in a different study [70]. I also observed
significantly higher abundances of Rikenellaceae in C57BL/6J male mice compared to female
C57BL/6J mice and B6.129S mice of both sexes. Rikenellaceae is a family in phylum
Bacteroidetes that is thought to interact with the intestinal immune system [105]. It has been
shown to be regulated by Interleukins (IL) 22 and 23, and associated with T-helper (Th) 17 cell
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development [220]. Additionally, higher abundances of Rikenellaceae have been observed in IL22 knockout mice [92] and myeloid differentiation primary response 88 (Myd88) deficient mice
[252]. It remains unknown whether alterations in Rikenellaceae can modify Th17 cell function,
but given the important role of Th17 cells and their associated cytokines in IBD [113], future
studies should investigate the impact of Rikenellaceae on Th17 cell function. I also observed
significantly higher relative abundances of Lachnospiraceae in B6.129S females, and
significantly higher relative abundance of Bacteroidales S24-7 in B6.129S males. Both taxa have
been negatively correlated to inflammation and pathogen infection [23], but more studies are
needed to elucidate any specific role in the immune response.

Overall, C57BL/6J mice also had significantly higher relative abundance of Bifidobacterium than
B6.129 mice and BALB/c mice. Bifidobacterium is commonly reported to have beneficial effects
on gut health [72,200,225]. Relatively high levels of Bifidobacterium in C57BL/6J mice has also
been reported elsewhere [83,204]. In mice, it has been shown to inhibit both DSS [72] and TNBS
colitis [204]. Administration of a mixture of Bifidobacterium and Lactobacillus strains prevented
TNBS colitis, and was associated with the expansion of gamma delta (γδ)-T cells and regulatory
T cells [204]. It may be that the presence of Bifidobacterium contributes to the colitis resistance
that C57BL6 mice are reported to exhibit. Additionally, female C57BL/6J mice had significantly
lower relative abundance of Bifidobacterium (less than 1% of the community) compared to male
C57BL/6J mice (approximately 4% of the community). Further studies are needed to determine
whether Bifidobacterium is associated with differences in colitis among mouse strains.

The BALB/c mouse microbiome was characterized by significantly higher relative abundance of
Rikenellaceae, Odoribacter, and Oscillospira. Odoribacter and Oscillospira are known to
produce short-chain fatty acids (SCFAs) and decreased levels are often reported in IBD patients
[82,169] . BALB/c mice also had a significantly lower relative abundance of Lactobacillus
compared to the other strains. Higher levels of Lactobacillus have been associated with
decreased inflammation [64,77], and perhaps lower levels of Lactobacillus may contribute to the
susceptibility of BALB/c mice to colitis. Although I did not induce TNBS colitis in BALB/c
mice, the literature reports that BALB/c mice that are exposed to TNBS develop Th2-driven
inflammation [9]. This is in contrast to B6.129S mice and C57BL/6J mice, which develop Th1

74
driven inflammation. Given the distinct differences in the microbiome composition shown here
between BALB/c mice and the other two strains, it may be that the difference in inflammatory
response is at least partially microbe-mediated, but further study is needed to test this hypothesis.

Given that the same sequencing and analysis protocols were used for all of the samples, the data
presented here suggests that mouse genetic background has a profound impact on the fecal
microbiome. These analyses have shown that the fecal microbiomes of mice from three
commonly used genetic backgrounds, C57BL/6J, B6.129S, and BALB/c are significantly
different. I also detected sex and vendor/acclimation time effects in the microbiomes of these
mice, which highlight the importance of considering these factors when designing experiments to
investigate the microbiome. Using mice that have acclimated for inconsistent amounts of time
could lead to variation in the microbiome results. Moreover, combining samples collected from
mice directly from the vendor with samples collected from mice from a different location will
likely introduce variation in the microbiome results. It is therefore imperative that researchers
consider the strain of the mouse used in a particular study when trying to put their own data into
the context of the literature. It may be that perceived relationships between certain taxa and a
particular outcome, specific to the strain of mouse selected. Perhaps the origin of conflicting
reports related to the association of a particular taxon and inflammation could be partly due to
previously unknown or under-appreciated mouse strain-specific microbiome configurations. This
data highlights the importance of carefully considering host factors when designing, analyzing,
and comparing microbiome studies.
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C57BL/6J

Purdue: Males n=9 Females n=4
Jackson: Males n=9

B6.ll9S

Purdue: Males n=6 Females n=20
Jackson: Males n=6

BALB/c

Harlan: Males n=12

Figure 4.1 Quantities and sex of mice strains used for analysis, separated by vendor
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Figure 4.3 Differences in beta-diversity of the fecal microbiomes of B6.129S, BALB/c, and
C57BL/6J mice. A. Bray Curtis metric shows separation of communities based on strain
(p<0.05). Separation occurs on PC1 and PC2, which explain 31.08% and 19.23% of the total
variation, respectively.
Significance was found using PERMANOVA. Significant
PERMDISP (p<0.05) indicates that dispersion may contribute to significance. B. Unweighted
UniFrac metric shows separation of communities based on strain (p<0.05). Separation occurs
on PC1 and PC2, which explain 18.75% and 14.25% of the total variation, respectively.
Significance was found using PERMANOVA. Significant PERMDISP (p<0.05) indicates that
dispersion may contribute to significance.
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Figure 4.5. Heatmap of significantly different taxa in each strain. Relative abundances
of taxa identified by ANCOM to be significantly different between mouse strains at
p<0.01. Blue represents a relative abundance of 0, and color gradient increases to
yellow as relative abundance increases. Superscript lowercase letters indicate which
taxa remained significant different after pairwise post- testing and correcting for
multiple corrections. Significance is considered an adjusted p value of less than 0.05
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Figure 4.8 Significantly different taxa associated with sex within strains. A. Histogram of the
effect sizes of taxa that Lefse identified as being significantly contributing to the differences
between mouse strains and sexes. B-E. Bar graphs of relative abundance of select genera in male
and female B6.129S mice and male and female C57BL6J mice. Significance found using
ANCOM followed by pairwise post-tests. P values were adjusted for multiple comparisons. **
p<0.01, ***p<0.001, ****p<0.0001. D. Bar graph of colitis scores of male and female C57BL6J
mice with chronic TNBS colitis. Asterisk indicates significance at p<0.05 using Mann-Whitney
test.
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CHAPTER 5.

SUMMARY

Inflammatory Bowel Disease (IBD) has two distinct phenotypes, Crohn’s Disease (CD) and
Ulcerative Colitis (UC). Both phenotypes are chronic, relapsing diseases with no defined cause
and no cure. Current treatment strategies focus on alleviating symptoms, and do not always result
in long term success. A widely used treatment option is anti-Tumor Necrosis Factor (TNF) drugs.
Tumor necrosis factor is a cytokine that is directly involved in the inflammatory process.
Blocking TNF results in decreased inflammation in patients that are responsive to treatment, but
a subpopulation of patients only respond for a limited time, if at all. Although the exact cause of
IBD is unknown, genetic and environmental factors, including the gut microbiome have all been
shown to play a role in IBD pathogenesis.

The gut microbiome is the complex community of microorganisms that inhabit the
gastrointestinal tract of humans and other animals. The gut microbiome is involved in various
biological processes, such as immune system homeostasis, metabolism, nutrient absorption, and
even mood. As such, studies concerning the role of the gut microbiome in various diseases are
numerous. In the context of IBD, studies have shown that patients have a markedly different gut
microbiome than that of healthy individuals. In general, the gut microbiomes of IBD patients
have reduced microbial diversity, which is thought to result in decreased resilience to disruptions
caused by stress, pathogenic infection, or other environmental triggers. In addition, alterations in
the proportions of taxonomic groups that have been associated with health and/or pathogenesis
are commonly observed. Gut microbiome differences have also been identified as a potential
determinant of whether or not a patient responds to treatment. Therefore, there is a critical need
for studies seeking to elucidate the relationship between the gut microbiome and IBD
pathogenesis.

The microbiome is a dynamic ecosystem, always responding to the host environment. Humans
have naturally high inter-individual variation in their microbiomes. Attempts to describe one
‘core’ ideal healthy human gut microbiome have been unsuccessful, as the gut microbiomes of
healthy humans still vary considerably. Laboratory mice are genetically similar, reside in the
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same immediate environment, are on identical diets, and experience similar environmental
exposures which allows for control of these confounders that are components of development of
IBD in people. Mouse models of IBD also provide a system for studies to focus on the specific
impact of one component of interest (in my case, TNF) on the microbiome during colitis. These
characteristics provide a powerful tool for microbiome research.

In theory, mouse colitis models provide an opportunity to investigate how specifically the gut
microbiome impacts colitis, while limiting confounding factors that lead to high variability.
However, the impact of host factors such as age, sex, strain, and vendor on the mouse gut
microbiota has been underappreciated. Therefore, the reproducibility and comparability of mouse
IBD studies across mouse strains and experimental designs may be reduced. The overall
objective of this work was to determine how TNF and host variables impact the mouse gut
microbiome during colitis. I set out to test three hypotheses:
1) Age, sex, and TNF affect the fecal microbiome of mice, and impact the severity of acute
TNBS colitis. To test this hypothesis, I compared the fecal microbiomes of male and
female B6.129S WT and Tnf-/- mice of different ages before and after acute TNBS colitis.
2) TNF, sex and disease severity impact the microbiome in chronic TNBS colitis and the
composition of the fecal microbiome will closely correlate with colitis severity. To test
this hypothesis, I compared the fecal, cecal, and mucus microbiomes of WT C57BL/6J
mice with chronic TNBS colitis, as well as the fecal microbiomes of C57BL/6J WT AND
Tnf-/- mice before and after chronic TNBS colitis.
3) The strain of mouse impacts the fecal microbiome. To test this hypothesis, I compared the
fecal microbiomes of unaltered, WT mice of three commonly used laboratory mouse
strains and identified taxa that are differentially abundant.

The increased availability of high-throughput sequencing allows researchers to generate massive
amounts of sequence data in a variety of experimental conditions. Consequently, the arsenal of
statistical tests and tools available for biological data is growing rapidly. Therefore, it is
important to understand the strengths and limitations of the available methods and its utility for a
dataset. The bulk of my analyses were performed with the QIIME (Quantitative Insights into
Microbial Ecology) pipeline. First, I analyzed the microbial diversity. This involves metrics that
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measure species richness, (the number of different taxa in a habitat) as well as species evenness
(the distribution of the taxon abundances in an environment). Furthermore, I examined the
microbial diversity within each mouse (alpha diversity) as well as between mice in different
conditions (beta diversity). To examine microbial community composition, I used the Linear
Discriminant Analysis Effect Size (LEfSe) and Analysis of Composition of Microbiomes
(ANCOM) methods. Simple Pearson and Spearman correlation methods have often been used to
predict correlations between taxa in a dataset and other environmental variables, but these do not
account for the unique features of microbiome data that I discussed previously. Simple
correlation methods can lead to spurious correlations and conclusions when used on
compositional data. I use newly introduced SParse InversE

Covariance Estimation

for Ecological ASsociation Inference

identify

(SPIEC-EASI)

method

to

co-occurrence

relationships in my data. I also performed Canonical Correspondence Analysis (CCA) to analyze
species-environment relationships and the interactions between sets of variables in my data.
Through this multi-faceted approach, I could pursue my objective and provide valuable insight
into the impact of host variables and TNF on the gut microbiome during colitis.

My first hypothesis was that age, sex, and TNF affect the fecal microbiome of mice and impact
the severity of acute TNBS colitis. Comparison of the baseline microbiome data between WT
and Tnf-/- B6.129S mice revealed significant differences in microbial diversity and community
composition before colitis. This suggests that TNF expression impacts the gut microbiome. I also
observed differences in the microbiomes of WT and Tnf-/- mice associated with sex, before and
after colitis. WT mice developed significantly more acute TNBS colitis than Tnf-/- mice, and WT
male mice developed the most severe colitis. Age analyses also revealed that younger mice
developed less colitis than older mice. Additionally, the microbiomes of younger and older mice
were significantly different from one another. Taken together, this data supports my hypothesis.
TNF was shown to significantly impact the fecal microbiome, as well as acute colitis
development. Sex differences in the fecal microbiome were found in both WT and Tnf

-/-

mice,

with the microbiomes of WT male mice (who developed more colitis), being significantly
different that the WT female mice. Additionally, CCA revealed that sex had the strongest
influence on the microbiome, followed by age and genotype, respectively. Colitis score was most
associated with genotype and age.
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My second hypothesis was that Tnf

-/-

mice will have less severe chronic TNBS colitis and a

distinct microbiome compared to WT mice and that sex impacts both the microbiome and colitis
severity of both genotypes. Additionally, the fecal, cecal, and colonic mucus microbiomes after
colitis will be distinct, and colitis severity will be most closely associated with the fecal
microbiome. I found that the fecal, cecal, and mucus microbiomes are distinct, and that the
mucus microbiome best reflects TNBS colitis. Sex did not impact the fecal microbiome of WT
C57BL6J mice, and Tnf

-/-

mice tended to have less colitis than WT mice. The results of the

chronic study have important implications for mouse studies that seek to understand the role of
the gut microbiome in inflammation. Future studies, especially those using TNBS, should
investigate the mucus microbiome in order to reveal associations that are likely directly related to
inflammation and relevant to human disease. I also show, in agreement with the results of the
acute study, that TNF impacts the gut microbiome in mice. A larger colitis study that samples the
fecal and mucus microbiome could utilize co-occurrence modeling to identify differential
microbial interaction networks between WT and Tnf -/- mice, this would provide a framework for
mechanistic studies to understand how TNF interacts with the microbiome. This data highlights a
critical gap in knowledge that is relevant to how human IBD is treated. Future human studies
should investigate how the human gut microbiome is impacted by TNF inhibitors. It is very
likely that duration of use, combination with antibiotic or other immunosuppressive therapies, as
well as host factors such as age and sex all result in varied therapeutic responses and long-lasting
effects on the microbiome.

Strain of mouse used differed between the experimental sets and led me to consider that the
microbiome may differ between strains of mice, which may affect disease outcome. Thusly, I
analyzed the microbiome of three commonly used strains of laboratory mice (C57BL/6J, B6.129,
and BALB/c) with the hypothesis that the fecal microbiomes of these strains would have distinct
microbiome profiles. I found that although the three strains were dominated by the same two
phyla, each strain tended to have a unique proportion of less abundant phyla, such as
Proteobacteria and Actinobacteria. At the genus level, the differences between each strain were
evident. There were also sex-specific microbiome differences within B6.129S mice and
C57BL/6J mice. These findings have profound implications. First, it suggests that each strain of
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mouse could have a distinct microbiome, and that the degree to which host factors, like sex,
affect each strain could be different. Second, although not directly tested here, these microbiome
differences may contribute to the different responses to TNBS colitis in mice of different strains.
This is crucial to consider when comparing the results of a study back to the literature. As
already discussed, the same colitis model can elicit different T cell responses in two different
mouse strains. It may be that these differences in immune responses are shaped by the
microbiomes specific to each strain, or they can be related to the genetics of the mouse. Future
studies could aim to further investigate these differences. In order to test how the microbiome
may influence colitis susceptibility, a carefully controlled study inducing colitis in several strains
of mice would be needed.

These studies provide a foundation for future work that could lead to a better understanding of
the role of the gut microbiome in IBD pathogenesis, as they have identified several taxonomic
groups that warrant further study. Future work could aim to elucidate the potential role of
Lactobacillus and Bifidobacterium in protecting C57BL/6J mice from colitis. Other studies could
focus on the role of sulfate reducing bacteria in colitis. Combining cytokine profiling with
microbiome studies of acute or chronic colitis could identify sex-specific differences in
inflammatory signaling and determine whether those differences correlate with sex differences in
the microbiome. Understanding sex-specificity in the context of human disease will be critical to
the development of personalized treatment options. The literature shows that the microbiome of
patients responsive to TNF inhibitor therapy is different from that of non-responsive patients.
This highlights the importance of unraveling the relationship between the microbiome and TNF
in colitis. To better understand the interactions between TNF (and TNF blockade) and the
microbiome, future studies could employ a microbiome transfer design, coupled with cytokine
profiling, to identify the contribution of the microbiome to immune responses in the presence
and absence of TNF. It would also be of great scientific benefit to conduct functional
comparisons between mouse strain microbiomes to determine if there are differences in
metabolic pathways associated with inflammation in each strain. The data presented here
highlight the difficultly in applying the knowledge of differentially abundant taxa associated with
colitis to other mouse and/or human studies. The microbiome consists of several taxonomic
groups who may occupy overlapping functional niches. This means that the proportional changes
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of one group of microbes may not directly translate to a loss or gain of function that impacts
colitis. Therefore, functional studies should be conducted. Identifying important trends, the in the
literature across mouse strains would be more feasible if we knew the differences in function
associated with colitis between mouse strains.

In this work, I have identified taxonomic differences in the microbiomes of mice during acute
and chronic TNBS colitis. These differences have been associated with sex, age, mouse strain,
vendor, and TNF production. These studies highlighted the importance of host factors in
microbiome studies and provided important data to the body of literature concerning the role of
the microbiome in colitis.
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APPENDIX A. NO SEX ASSOCIATED DIFFERENCES IN COLITIS IN
MICE LACKING TNF

12,-

10·

Figure A. Bar graph of semi quantitative colitis scores of male and female Tnf-/- mice treated
with TNBS and SHAM. Significance determined using t-test. **p<0.001. Scores shown as mean
± S.E.M
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APPENDIX B. NO SIGNFICANT SEX ASSOCIATED DIFFERENCES IN
THE FECALMICROBIOMES OF WT MICE PRE-COLITIS
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Figure B. Beta diversity analysis of the Unweighted UniFrac metric reveals no significant
differences in the microbiomes of WT mice pre-colitis.
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